CME Review Article

Keeping up with the clinical advances: schizophrenia

This activity is provided by the Neuroscience Education Institute.

Additionally provided by the American Society for the Advancement of Pharmacotherapy.
CME Information

Released: July 25, 2019
CME credit expires: May 15, 2022

Learning Objectives
After completing this activity, you should be better able to:

- Differentiate the mechanisms of action of new and emerging antipsychotics
- Evaluate the latest clinical data on new and emerging antipsychotics

Accreditation and Credit Designation Statements
The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NEI designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to earn CME credits.

The American Society for the Advancement of Pharmacotherapy (ASAP), Division 55 of the American Psychological Association, is approved by the American Psychological Association to sponsor continuing education for psychologists. ASAP maintains responsibility for this program and its content.

The American Society for the Advancement of Pharmacotherapy designates this program for 1.5 CE credits for psychologists.

Nurses and Physician Assistants: for all of your CE requirements for recertification, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content of this activity pertains to pharmacology and is worth 1.5 continuing education hours of pharmacotherapeutics.

Optional Posttest and CME Credit Instructions
1. Read the article
2. Complete the posttest, available only online at www.neiglobal.com/CME (under “CNS Spectrums”)
3. Print your certificate (passing score = 70% or higher)

Questions? call 888-535-5600, or email CustomerService@neiglobal.com

Peer Review
This content has been peer reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosures
All individuals in a position to influence or control content are required to disclose financial relationships of any amount with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

Authors
Amanda Krogmann, BSc, is affiliated with Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry in Berlin, Germany. Ms Krogmann has no financial relationships to disclose.

Luisa Peters, BSc, is affiliated with Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry in Berlin, Germany. Ms Peters has no financial relationships to disclose.

Laura von Hardenberg, MPhil, is affiliated with Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry in Berlin, Germany. Ms von Hardenberg has no financial relationships to disclose.

Katja Bödeker, PhD, is affiliated with Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry in Berlin, Germany. Dr. Bödeker has no financial relationships to disclose.

Viktor B. Nöhles, MA, is affiliated with Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry in Berlin, Germany. Mr. Nöhles has no financial relationships to disclose.

Christoph U. Correll, MD, is affiliated with Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry in Berlin, Germany; the Zucker Hillside Hospital, Psychiatry Research, Northwell Health in Glen Oaks, New York, USA; and Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine in Hempstead, New York, USA. Dr. Correll has been a consultant/advisor to or has received
honoraria from: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Boehringer-Ingelheim, Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda, and is also a shareholder of LB Pharma.

No writing assistance was utilized in the production of this article.

CNS Spectrums Peer Review

All CME articles are peer reviewed in accordance with the strict standards of CNS Spectrums and in accordance with requirements and recommendations of the International Committee of Medical Journal Editors. The Editorial policies of the journal CNS Spectrums and peer review of all articles that appear in the journal is managed independently by Cambridge University Press and no financial relationship exists between the CME provider and Cambridge for this service.

The Content Editor, an NEI Peer Reviewer, and the Planning Committee have no financial relationships to disclose.

Disclosure of Off-Label Use

This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural and Linguistic Competency

A variety of resources addressing cultural and linguistic competency can be found at this link: www.neiglobal.com/go/cmerg

Providers

This activity is provided by NEI. Additionally provided by the ASAP.

Support

This activity is supported by an unrestricted educational grant from Indivior.
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities

Amanda Krogmann,1,† Luisa Peters,1,† Laura von Hardenberg,1 Katja Bödeker,1 Viktor B. Nöhles,1 and Christoph U. Correll1,2,3,*

1 Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
2 Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, USA
3 Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA

Schizophrenia remains one of the most severe medical diseases. Current dopamine modulating first-generation and second-generation antipsychotics target mainly positive symptoms, but not inadequately negative and cognitive symptoms. Additional challenges include non-adherence and adverse effects, especially cardiometabolic dysregulation. This review evaluates new/emerging pharmacological treatments for schizophrenia. Therapies targeting total symptoms include cannabidiol, D3 antagonist/5-HT1A partial agonist F17464, lumateperone (ITI-007), phosphodiesterase 10A (PDE10A) inhibitors MK-8189 and TAK-063, sodium nitroprusside, and trace amine-associated receptor-1 (TAAR1) agonist RO5263397 and SEP-363856. Treatments targeting negative symptoms include the PDE10A inhibitor LuAF-11167, 5-HT2A inverse agonist pimavanserin, sigma-2/5-HT2A antagonist roluperidone (MIN-101), and d-aminooxidase (DAAO) inhibitor TAK-831. Agents targeting primarily cognitive dysfunction are the glycine transporter-1 inhibitor BI-425809 and cannabidiol. Therapies targeting residual positive symptoms/treatment-resistant schizophrenia include pimavanserin, dopamine D1/D2 antagonist LuAF-35700, and DAAO inhibitor sodium benzoate. Two new long-acting injectable antipsychotic formulations, Aripiprazole Lauroxil NanoCrystal® and the first subcutaneous injectable LAI Perseris (RBP-7000), were recently approved by U.S. Food and Drug Administration, and positive results were announced for Risperidone ISM®, each achieving therapeutic levels within 24 hours, without need for initial oral cotreatment/loading injection-strategies. Paliperidone palmitate 6-monthly intramuscularly injectable and Risperidone subcutaneously TV46000 are currently under investigation. Finally, the samidorphan + olanzapine combination targets reduced weight gain liability, while maintaining olanzapine’s efficacy. Most of these trial programs are still ongoing or have yielded mixed or even negative results. Thus, additional mechanisms of action and agents require study to improve schizophrenia outcomes for total/positive symptoms with reduced adverse effects, but also cognitive symptoms, negative symptoms, and treatment resistance, the areas of greatest need in schizophrenia currently.

Received 15 May 2019; Accepted 4 June 2019

Key words: Schizophrenia, psychopharmacology, randomized controlled trials, antipsychotics, phases 2 and 3.

Introduction

Schizophrenia is a still all-too-often chronic and debilitating psychiatric disorder that is characterized by a combination of positive and negative symptoms, cognitive dysfunction, affective and motor disturbances that often result in functional impairment and poor quality of life.1,2 Current treatment guidelines suggest long-term treatment with antipsychotic medications in conjunction with psychological interventions, for people with first episode psychosis, an acute exacerbation or recurrence of psychosis.3 Despite pharmacologic advances in recent years, an effective treatment of schizophrenia remains an issue, as knowledge about the pathophysiology of this complex disorder is lacking.1,4 The most challenging components of treatment effectiveness are adherence and efficacy for negative and cognitive as well as residual positive symptoms and adverse effects.1

Dopamine modulating antipsychotics remain the primary and only currently approved treatment for schizophrenia, and over the past years many different
antipsychotics have been developed and tested for their efficacy and safety in reducing acute symptoms of schizophrenia and maintaining stability. However, currently available drugs are mostly effective against positive symptoms (i.e., hallucinations, delusions, disorganized thought or speech, and bizarre behaviors). This situation leaves most patients with diverse residual symptoms relatively untreated, especially negative symptoms (lack of motivation, drive, enjoyment, social interactions) and cognitive dysfunction (deficits in attention, memory, executive functioning, grasp of social situations/interactions), which lead to poor quality of life outcomes and lifelong impairments.

As cognitive and negative symptoms persist for most of the patients’ lives, to date, there are no FDA-approved medications for negative and cognitive symptoms, and augmentation strategies have been largely disappointing so far.

Furthermore, as at least positive symptoms in schizophrenia have primarily been associated with dopamine dysfunction, all currently available effective antipsychotics have dopamine D2 receptor occupancy as a key feature, which is also associated with a varying degree of adverse effects, including motor impairments and prolactin abnormalities, with additional dopamine or off-target receptor activity-related effects on sedation, weight gain, metabolic disturbances and cardiovascular risk factors, morbidity and mortality.

In addition, too much dopamine blockade has been associated with secondary negative and cognitive symptoms.

However, drugs with dopamine D2 receptor occupancy have remained the only approved and effective pharmacologic treatment for schizophrenia, since its discovery in the 1950s. Currently, only clozapine, which has considerable adverse effects, has been found superior to other antipsychotics in treatment-resistant schizophrenia, defined as a failure to at least two nonclozapine antipsychotics. Thus, less side-effect-prone agents in monotherapy or as augmentation are needed for patients with suboptimal positive symptom response or treatment-resistance.

Recent findings suggest that the core pathophysiology of schizophrenia may also involve dysfunction of glutamatergic, serotonergic, cholinergic, and gamma-aminobutyric acid (GABA) signaling, with an imbalance within any of these influencing the entire system.

Therefore, novel treatment approaches have also been focusing on molecular targets beyond the dopamine hypothesis, including glutamate, serotonin, acetylcholine, GABA, and inflammatory cytokines.

Due to the goal of maintenance treatment and long-standing problems with adherence in schizophrenia, long-acting injectable antipsychotics (LAIs) have been developed and largely shown benefits for prevention of relapse, hospitalization, and mortality in patients with schizophrenia. Novel LAI formulations have emerged, aiming to improve acceptability and avoid the need for oral cotreatment or loading strategies.

Therefore, this selective review aimed to (i) summarize the mechanisms of action and, if available, the results of novel, emerging, and currently investigated pharmacologic treatments for total, negative, and cognitive symptoms of schizophrenia, as well as residual and resistant positive symptoms, (ii) summarize the latest clinical data of newly approved formulations of LAIs, and (iii) evaluate the data for the addition of opioid receptor modulation to mitigate olanzapine-associated weight gain.

Methods

We conducted a selective review of (i) different pharmacological drug targets for the treatment of total, negative, and cognitive, as well as residual or resistant positive symptoms of schizophrenia, (ii) new FDA-approved and investigated LAIs, and (iii) samidorphan-olanzapine combination. For this purpose, we conducted in March 2019 a series of targeted literature searches in PubMed and clinicaltrials.gov for “schizophrenia” paired together with the following mechanisms of action or psychopharmacological agents: phosphodiesterase 9 inhibitor, PDE-9 inhibitor, phosphodiesterase 9 (PDE9) inhibitor, phosphodiesterase 10A (PDE10A) inhibitor, d-amino acid oxidase (DOAA) inhibitor, cannabidiol, glycine transporter-1 (GLYT1) inhibitor, dopamine D1 antagonist, dopamine D1 partial agonist, dopamine D2 antagonist, dopamine D2 partial agonist, dopamine D3 antagonist, dopamine D3 partial agonist, trace amine-associated receptor-1 (TAAR1) agonist, 5-HT2A inverse agonist, sigma-2/5-HT2A antagonist, lumateperone (ITI-007), rolupiderone (MIN-101), sodium benzoate, sodium nitroprusside, LuAF-11167, LuAF-35700, BI-425809, F17464, MK-8189, RO5263397, SEP-363856, TAK-063, TAK-831, Aripiprazole Lauroxil NanoCrystal® or Aristada Initio, Doria® or risperidone ISM®, paliperidone palmitate, risperdone extended release, TV-46000, Perseris and RBP-7000. Excluded were agents or trials evaluating patients with other psychotic disorders than schizophrenia, or mixed samples.

Results

Total symptoms of schizophrenia (including positive and negative symptoms)

Although many first- and second-generation antipsychotics are available, all modulate dopamine with or without serotonergic transmission modulation, but additional mechanisms of actions conferring efficacy, either added on separately or combined with dopamine-serotonin antagonism, are needed. Furthermore,
improved safety and tolerability also remains a goal. Several agents are at different stages of testing.

**Cannabidiol**

While tetrahydrocannabinol (THC), the major component of cannabis, is pro-psychotic, the potential anti-psychotic and pre-cognitive properties of cannabidiol for schizophrenia and its efficacy for other neuropsychiatric disorders are actively being pursued.43–45

In an exploratory 6-week, double-blind study, patients with schizophrenia were randomized to cannabidiol ($n = 43$) or placebo ($n = 45$) added to preexisting antipsychotics.46 Although no differences between cannabidiol and placebo emerged regarding the Positive and Negative Syndrome Scale (PANSS) total or negative and general scale scores, cannabidiol had significantly lower PANSS positive scores at week 6. Furthermore, cannabidiol was superior to placebo in being rated as improved (Clinical Global Impressions-Improvement (CGI-I)) and as not severely unwell (CGI-Severity). However, cannabidiol was not superior to placebo on the Global Assessment of Functioning (GAF) Scale or the Brief Assessment of Cognition (BACS) (Table 2). Cannabidiol was well tolerated, with similar adverse event frequencies between cannabidiol and placebo.

**F17464**

F17464 is an oral, selective D₃ antagonist/5-HT₁A partial agonist that is developed for the treatment of schizophrenia.47

In a phase-II, double-blind, randomized, placebo-controlled, parallel-group 6-week trial,48 patients ($n = 134$) with acute exacerbation of schizophrenia were randomized to 40 mg/day F17464 or placebo. The F17464 group was significantly superior to placebo in reducing the PANSS total score, PANSS positive and general subscale score, and of the PANSS Wallwork factors, which correspond to cognitive functioning. However, F17464 did not differentiate from placebo on the PANSS negative and CGI-S scores (Table 2).48

Adverse events were comparable to placebo. Overall, results of this phase-II study demonstrated therapeutic efficacy in improving total, positive, and PANSS-derived cognitive symptoms in acutely exacerbated schizophrenia patients, with a favorable safety profile.48

**Lumateperone (ITI-007)**

Lumateperone, also known as ITI-007, is an investigational agent with simultaneous modulation of serotonin, dopamine, and glutamate, which is being developed for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric/neurodegenerative diseases. The FDA has accepted the new drug application (NDA) for lumateperone for the treatment of acutely exacerbated schizophrenia in December 2018.

Lumateperone acts as a presynaptic partial agonist and postsynaptic antagonist at dopamine D₂ receptors with functional mesolimbic/mesocortical selectivity.49 In addition, it has potent serotonin 5-HT₂₃A receptor antagonism, serotonin transporter inhibition, and stimulates phosphorylation of glutamatergic N-methyl-D-aspartate (NMDA) GluN₂B receptors, likely downstream of dopamine D₁ receptor intracellular signaling.49

Recently, the additional and unique increase of AMPA currents via the mTOR protein pathway has been described.50

At the therapeutic dose of 60 mg/day, lumateperone fully saturates 5-HT₂₃A receptors, at modest levels of dopamine receptor occupancies (30–40%), at least partially due to its wider separation (60-fold) between its affinity for 5-HT₂₃A receptors and D₂ receptors, compared to other second-generation antipsychotics, including risperidone (12-fold) and aripiprazole (0.18-fold).51

Lumateperone has been investigated in three placebo-controlled trials of acutely exacerbated schizophrenia, two of which included risperidone for assay sensitivity as an active comparator, and all conducted in the USA only.52 In a 4-week, phase-Ib clinical trial ($n = 335$; ITI-007-005), ITI-007 showed statistically significant efficacy vs. placebo in improving schizophrenia symptoms, measured with the PANSS total score and its subscale scores at a dose of 60 mg/day (but not at 120 mg/day), and at a similar effect size as risperidone.52

Compared to risperidone 4 mg/day, ITI-007 was superior at reducing negative symptoms, as well as on key safety and tolerability measures including prolactin, body weight, and glucose and lipid levels.52 In a first 4-week, phase-III trial ($n = 440$; ITI-007-301), lumateperone 60 mg/day separated from placebo regarding schizophrenia symptoms both in PANSS total and CGI-S.50 Notably, although lumateperone 40 mg/day was not superior to placebo regarding PANSS total scores, the 40 mg/day group was significantly superior regarding the CGI-S and PANSS positive subscale score (although not formally tested as the primary outcome did reach statistical significance), like the 60 mg/day group (Table 2). In a second phase-III trial lasting 6 weeks ($n = 695$; ITI-007-302), however, lumateperone 60 mg/day as well as 20 mg/day did not separate from placebo regarding schizophrenia symptoms, while risperidone 4 mg/day did (Table 2).50 Nevertheless, although risperidone separated from placebo, it also had the greatest dropout rate, with patients dropping out early being potentially the less responsive patient subgroup, and the placebo effect was much larger than in the other two trials, making the results less reliable than in the first two trials. In terms of adverse effects, lumateperone separated on few symptoms from placebo, including only somnolence, sedation,
| Treatment | Company | Phase | Receptor/mechanism of action | Indication | Adverse effects |
|-----------|---------|-------|-----------------------------|------------|----------------|
| **Target: total symptoms (including positive and negative symptoms)** |
| Cannabidiol (add-on) | N/A | N/A | Partial cannabinoid1 receptor antagonist, calcium channel modulator | Schizophrenia, other neuropsychiatric disorders | Dyslipidemia, nausea, sedation |
| F17464 (monotherapy) | Pierre Fabre Medicament | Phase-II | D3 antagonist, 5-HT1A partial agonist | Schizophrenia | Insomnia, agitation, and increased triglycerides |
| Lumateperone (ITI-007) (monotherapy) | Intracellular Medications (ITI) | Phase-III, under FDA review | 5-HT2A antagonist, 5-HT transport inhibitor, presynaptic D2 partial agonist and postsynaptic D2 antagonist, D1-regulated NMDA and AMPA agonist | Schizophrenia, bipolar depression, agitation in patients with dementia, neuropsychiatric/neurodegenerative diseases | Somnolence, dry mouth, headache |
| MK-8189 (monotherapy) | Merck Sharp & Dohme Corp. | Phase-II | PDE10A inhibitor | Schizophrenia | N/Av |
| RO5263397 (monotherapy) | Roche | Phase-III | TAAR1 agonist | Schizophrenia | N/Av |
| SEP-363856 (monotherapy) | Sunovion, Sumitomo-Dainippon | Phase-III | TAAR1 agonist | Schizophrenia | Somnolence, nausea, diarrhea, dyspepsia |
| Sodium Nitroprusside (monotherapy) | N/A | N/A | Nitric oxide donor | Schizophrenia | N/Av,62 Akathisia, dystonia,57 |
| TAK-063 (monotherapy) | Takeda | Phase-II | PDE10A inhibitor | Schizophrenia | N/Av |
| **Target: negative symptoms** |
| LuAF-11167 (monotherapy) | Lundbeck | Phase-II | PDE10A inhibitor | Schizophrenia | N/Av |
| Pimavanserin (add-on) | Acadia | Phase-II | 5-HT2A inverse agonist | Schizophrenia, major depressive disorder, Parkinson’s psychosis, psychosis in Alzheimer’s disease | N/Av76 |
| Roluperidone (MIN-101) (monotherapy) | Minerva Neurosciences | Phase-III | 5-HT2A antagonist, sigma2 antagonist, alpha1-adrenergic antagonist | Schizophrenia | Headache, anxiety, insomnia, schizophrenia symptoms, asthenia, nausea, and somnolence |
| TAK-831 (monotherapy) | Takeda | Phase-II | D-amino acid oxidase (DAAO) inhibitor | Schizophrenia, cerebellar ataxia | N/Av57 |
| **Target: cognitive dysfunction** |
| BI-425809 (add-on) | Boehringer-Ingelheim | Phase-II | Glycine-transporter-1 (GLYT-1) inhibitor | Schizophrenia | N/A66,87 |
| Treatment | Company | Phase | Receptor/mechanism of action | Indication | Adverse effects |
|-----------|---------|-------|-----------------------------|------------|-----------------|
| Cannabidiol (add-on) | N/A | N/A | Partial cannabinoid$_1$ receptor antagonist, calcium channel modulator | Schizophrenia, other neuropsychiatric disorders | sedation$^{48}$ |
| **Target: residual and treatment-resistant positive symptoms** | | | | | |
| LuAF-35700 (monotherapy) | Lundbeck | Phase-III | D$_1$ > D$_2$ antagonist 5-HT$_2A$ antagonist 5-HT$_6$ occupancy | Treatment-resistant schizophrenia | N/A$^{91}$ |
| Pimavanserin (add-on) | Acadia | Phase-III | 5-HT$_2A$ inverse agonist | Schizophrenia, major depressive disorder, Parkinson’s psychosis, psychosis in Alzheimer’s disease | Headache, somnolence, insomnia$^{93}$ |
| Sodium benzoate (monotherapy) | N/A | N/A | D-amino acid oxidase (DAAO) inhibitor | Treatment-resistant schizophrenia | N/A$^{94,95}$ |
| **Target: reducing antipsychotic non-adherence** | | | | | |
| Aripiprazole Lauroxil NanoCrystal® Dispersion (Aripiprazole Lauroxil NCD; Aristada Initio)(monotherapy) | Alkermes | FDA-approved | Partial D$_2$ agonist Partial 5-HT$_2A$ agonist 5-HT$_2A$ antagonist | Schizophrenia | Injection pain, headache, weight gain, insomnia, dyspepsia, and anxiety$^{100}$ |
| Paliperidone Palmitate 6-monthly formulation (monotherapy) | Janssen | Phase-III | 5-HT$_2A$ antagonist D$_2$ antagonist | Schizophrenia | N/A |
| Perseris™ Risperidone s.c. injection (RBP-7000) (monotherapy) | Indivior | FDA-approved | 5-HT$_2A$ antagonist D$_2$ antagonist | Schizophrenia | Injection site pain, headache, sedation/somnolence, and weight gain$^{111}$ |
| Risperidone extended release s.c. injection (TV46000) (monotherapy) | Teva | Phase-III | 5-HT$_2A$ antagonist D$_2$ antagonist | Schizophrenia | N/A |
| Risperidone ISM® (Doria®) (monotherapy) | Laboratorios Farmacéuticos Rovi, | Phase-III | 5-HT$_2A$ antagonist D$_2$ antagonist | Schizophrenia | N/A |
| **Target: amelioration of adverse effects** | | | | | |
| Samidorphan + Olanzapine (ALKS3831) (monotherapy) | Alkermes | Phase-III, under FDA review | μ-opioid antagonist + olanzapine | Olanzapine-induced weight gain + schizophrenia | Weight gain, somnolence, dry mouth, anxiety, headache, and schizophrenia$^{128}$ |

AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, N/A, not applicable; N/Av, not available, NMDA, N-methyl-D-aspartate, PDE, phosphodiesterase, s.c. , subcutaneous, TAAR, trace amine-associated.
TABLE 2. Selected novel and emerging pharmacological treatments for schizophrenia targeting total (including positive and negative) symptoms

| References                  | Total n | Trial duration | Active group(s) | Comparison(s) groups | Results | Comments |
|-----------------------------|---------|----------------|-----------------|----------------------|---------|----------|
| **Cannabidiol**             |         |                |                 |                      |         |          |
| McGuire et al. (2018)       | 88      | 6 weeks        | Cannabidiol 1000 mg/day + preexisting antipsychotic (n = 43) | Placebo + preexisting antipsychotic (n = 45) | PANSS positive Treatment difference = −1.4; 95% CI = −2.5, −0.2; p = .019 | Positive study: Cannabidiol was significantly superior in improving PANSS positive symptoms (CGI-I and CGI-S scores, compared to placebo). No separation from placebo on the PANSS negative and general subscale, PANSS total, GAF, and BACS. |
|                             |         |                |                 |                      | PANSS negative Treatment difference = 0; 95% CI = −1.3, 1.4; p = .365 |
|                             |         |                |                 |                      | PANSS general Treatment difference = −1.3; 95% CI = −3.2, 0.7; p = .196 |
|                             |         |                |                 |                      | PANSS total Treatment difference = −2.8; 95% CI = −6.5, 0.9; p = .133 |
|                             |         |                |                 |                      | CGI-I Treatment difference = −0.5; 95% CI = −0.8, −0.1; p = .018 |
|                             |         |                |                 |                      | CGI-S Treatment difference = −0.3; 95% CI = −0.5, 0.0; p = .044 |
|                             |         |                |                 |                      | GAF Treatment difference = 3.0; 95% CI = −0.4, 6.4; p = .06 |
|                             |         |                |                 |                      | BACS Treatment difference: 1.31; 95% CI = −1.0, 2.72; p = .068 |
| **F17464**                  |         |                |                 |                      |         |          |
| Bitter et al. (2019)        | 134     | 6 weeks        | F17464 40 mg/day (n = 67) | Placebo (n = 67) | PANSS total Treatment difference (SE) = −6.2 (2.5), p = .02 | Positive study: F17464 was significantly superior in reducing PANSS total, as well as PANSS positive and general subscale score, and Wallwork factors of the PANSS (cognitive functioning), compared to placebo. No differences in PANSS negative and CGI-S. |
|                             |         |                |                 |                      | PANSS positive p = .03, non-parametric test |
|                             |         |                |                 |                      | PANSS negative No statistical significance |
|                             |         |                |                 |                      | PANSS general Treatment difference (SE) = −3.6 (1.3), p < .01 |
|                             |         |                |                 |                      | Wallwork factors Treatment difference (SE) = −0.85 (0.4), p = .03 |
|                             |         |                |                 |                      | CGI-S No statistical significance |
| **Lumateperone (ITI-007)**  |         |                |                 |                      |         |          |
| Lieberman et al. (2016)     | 335     | 4 weeks        | ITI-007 60 mg/ day (n = 84) ITI-007 120 mg/ day (n = 83) | Placebo (n = 85) Risperidone 4 mg/ day (n = 82) | PANSS total ITI-007 60 mg/day vs. placebo: p = .017, effect size = .42 | Positive study: ITI-007 60 mg was significantly superior to placebo in reducing PANSS total and PANSS positive subscale scores and CGI-S. 120 mg did not separate from placebo. |
|                             |         |                |                 |                      | ITI-007 120 mg/day vs. placebo: p = .708, effect size = .07 |
|                             |         |                |                 |                      | Risperidone 4 mg/day vs. placebo: p = .013, effect size = .44 |
|                             |         |                |                 |                      | ITI-007 60 mg/day vs. placebo: p = .002, effect size = .50 |
|                             |         |                |                 |                      | ITI-007 120 mg/day vs. placebo: p = .272, effect size = .17 |
|                             |         |                |                 |                      | Risperidone 4 mg/day vs. placebo: p = .002, effect size = .51 |
|                             |         |                |                 |                      | Positive study: ITI-007 60 mg was significantly superior to placebo in reducing PANSS total and PANSS positive subscale scores and CGI-S. 120 mg did not separate from placebo. |
| References | Total | Trial duration | Active group(s) | Comparison(s) groups | Results | Comments |
|------------|-------|----------------|----------------|----------------------|---------|----------|
| Vanover et al. (2018)\(^\text{a,b}\), Study ITI-007-301 | 440 4 weeks | ITI-007 60 mg/day \((n=150)\) ITI-007 40 mg/day \((n=150)\) | Placebo \((n=150)\) | PANSS negative | ITI-007 60 mg/day vs. placebo: \(p=.230\), effect size = .19 ITI-007 120 mg/day vs. placebo: \(p=.319\), effect size = .16 Risperidone 4 mg/day vs. placebo: \(p=.914\), effect size = .02 | | |
| | | | | PANSS general | ITI-007 60 mg/day vs. placebo: \(p=.040\), effect size = .33 ITI-007 120 mg/day vs. placebo: \(p=.217\), effect size = .17 Risperidone 4 mg/day vs. placebo: \(p=.003\), effect size = .48 | | |
| | | | | CGI-S | ITI-007 60 mg/day vs. placebo: treatment difference: \(-2.6\); \(p=.164\) | & Positive study: ITI-007 60 mg was significantly superior to placebo regarding PANSS total, PANSS positive, and CGI-S Score |
| | | | | MK-8189 titrated from 4 mg/day to 12 mg/day over 7 days and then maintained for another 3 weeks \((n=90)\) Placebo \((n=89)\) Risperidone titrated from 2 mg/day to 6 mg/day over 7 days and then maintained for another 3 weeks \((n=45)\) | PANSS total | MK-8189 vs. placebo \(p=.074\) Risperidone vs. placebo \(p=.033\) MK-8189 vs. risperidone \(p=.440\) | & Negative study: Neither dose of ITI-007 separated from placebo on the primary endpoint (PANSS total), but risperidone did; a high placebo response (>15 points on the total PANSS score) was observed in this study. |
| MK-8189 \(\text{https://clinicaltrials.gov/ct2/show/results/NCT03055338}\) | 224 4 weeks | MK-8189 titrated from 4 mg/day to 12 mg/day over 7 days and then maintained for another 3 weeks \((n=90)\) Placebo \((n=89)\) Risperidone titrated from 2 mg/day to 6 mg/day over 7 days and then maintained for another 3 weeks \((n=45)\) | PANSS total | MK-8189 vs. placebo \(p=.074\) Risperidone vs. placebo \(p=.033\) MK-8189 vs. risperidone \(p=.440\) | & Negative study: MK-8189 did not separate from placebo on PANSS total, but risperidone did. |

(Continued)
| References       | Total n | Trial duration | Active group(s) | Comparison(s) groups | Results                                                                 | Comments                                                                                     |
|------------------|---------|----------------|-----------------|----------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| **SEP-363856**   | 245     | 4 weeks        | SEP-363856 flexible dosing: 50 mg/day or 75 mg/day (n = 120) | Placebo (n = 125) | PANSS total: \( p = .0001, \text{effect size} = .45 \) | Positive study: SEP-363856 was significantly superior to placebo on PANSS total and all three subscale scores, CGI-A, BNSS, and MADRS. |
| Poola et al. (2018) |         |                |                 |                      | PANSS positive: \( p = .019, \text{effect size} = .32 \)                   |                                                                                               |
|                  |         |                |                 |                      | PANSS negative: \( p = .008, \text{effect size} = .37 \)                   |                                                                                               |
|                  |         |                |                 |                      | PANSS general: \( p < .001, \text{effect size} = .51 \)                    |                                                                                               |
|                  |         |                |                 |                      | CGI-S: \( p < .001, \text{effect size} = .52 \)                           |                                                                                               |
|                  |         |                |                 |                      | BNSS: \( p < .001, \text{effect size} = .48 \)                            |                                                                                               |
|                  |         |                |                 |                      | MADRS: \( p = .02, \text{effect size} = .32 \)                            |                                                                                               |
| **Sodium nitroprusside** | 20 | 4 weeks | Sodium nitroprusside 0.5 μg/kg/min for 4 h (n = 10) | Placebo (n = 10) | BPRS-18: \( \rho < .001, F_{1,18} = 12.91 \) | Positive study: sodium nitroprusside was significantly superior to placebo, within 4 h, on the BPRS. |
| Hallak et al. (2013) |         |                |                 |                      |                                                                             |                                                                                               |
|                  | 42      | 4 weeks        | Sodium nitroprusside 0.5 μg/kg/min for 4 h (n = 21) | Placebo (n = 21) | PANSS: No statistical significance | Negative study: Sodium nitroprusside failed to separate from placebo on the primary endpoint (PANSS total). |
| Wang et al. (2018) |         |                |                 |                      |                                                                             |                                                                                               |
| **Stone et al. (2016)** | 20 | 4 weeks | Sodium nitroprusside 0.5 μg/kg/min for 4 h (n = 10) | Placebo (n = 10) | WAIS: No statistical significance | Negative study: Sodium nitroprusside failed to separate from placebo on the primary endpoint (PANSS total). |
|                  |         |                |                 |                      | PANSS negative: \( p > .75, \text{effect size} = .095 \)                   |                                                                                               |
|                  |         |                |                 |                      | BPRS-18: \( p = .81, \text{effect size} = .11 \)                           |                                                                                               |
|                  |         |                |                 |                      | SWM: \( p = .2, \text{effect size} = .30 \)                               |                                                                                               |
|                  |         |                |                 |                      |                                                                             |                                                                                               |
| **Brown et al. (2019)** | 52 | 2 weeks | Sodium nitroprusside 0.5 μg/kg/min for 4 h (n = 18) | Placebo + placebo (n = 18) | PANSS total: \( z = -.93, p = .35 \) | Negative study: Sodium nitroprusside failed to separate from placebo on the primary endpoint (PANSS total). |
|                  |         |                |                 |                      | PANSS positive: \( z = -.79, p = .43 \)                                 |                                                                                               |
|                  |         |                |                 |                      | PANSS negative: \( z = -.19, p = .85 \)                                  |                                                                                               |
| **TAK-063**      | 164     | 6 weeks        | TAK-063 20 mg/day (n = 83) | Placebo (n = 81) | Least-squares mean difference vs. placebo (standard error) = −5.46 (3.44); \( p = .115 \), effect size = .308 | Negative study: TAK-063 failed to separate from placebo on the primary endpoint (PANSS total). |
| Macek et al. (2019) |         |                |                 |                      |                                                                             |                                                                                               |

BACS, Brief Assessment of Cognition in Schizophrenia; BNSS, Brief Negative Symptom Scale; BPRS-18, 18-Item Brief Psychiatric Rating Scale; CBD, Cannabidiol; CGI-I, Clinical Global Impressions Scale – Improvement; CGI-S, Clinical Global Impressions Scale – Severity; CI, confidence interval; GAF, Global Assessment of Functioning; MADRS, Montgomery-Asberg Depression Rating Scale; OR, odds ratio; PANSS, Positive and Negative Syndrome Scale; SOC, standard of care; SWM, Spatial Working Memory; WAIS, Wechsler Adult Intelligence Scale.
and fatigue (Table 1). However, these adverse effects were generally only mild or moderate, and lumateperone was associated with low and placebo-like discontinuation rates.50

Finally, in phase 1 of a recently completed study (n = 302, ITI-007-303),53 investigating the safety of ITI-007 in an open-label setting in patients with stable schizophrenia switching from standard-of-care (SOC) antipsychotics to lumateperone, 6 weeks of treatment with lumateperone led to significant improvements in both schizophrenia symptoms and key cardiometabolic parameters, such as LDL-cholesterol and triglycerides as well as prolactin levels. After only 2 weeks of switching back to SOC antipsychotics, the safety variables that had significantly improved trended back to pre-lumateperone baseline and were not significantly improved anymore.54 Interestingly, in this study program, lumateperone was dosed in the evening, and the already-low adverse event rates seen in the acute studies in which AM dosing had been applied were further reduced.

In phase 2 of the same study (n = 603, ITI-007-303)54 patients were enrolled for a planned treatment duration of up to 1 year. As the study is ongoing, data reflect an interim data cut that includes observed cases for those subjects who have had completed each visit (300 days, n = 184). After 300 days of treatment, lumateperone led to significant improvements in both schizophrenia symptoms (Table 2) and key cardiometabolic parameters, such as body weight and total cholesterol, LDL-cholesterol as well as prolactin levels.54 These results imply that patients with stable symptoms on other antipsychotics may further improve when switched to lumateperone.54

Overall, lumateperone represents a novel approach, with a unique mechanism of action, which seems to be promising in enhancing efficacy with a favorable safety profile.

**Phosphodiesterase 10A (PDE10A) inhibitors**

Phosphodiesterase 10A (PDE10A) inhibitors are expected to modulate via cAMP- and cGMP-dependent mechanisms both the dopamine D1-direct and D2-indirect striatal pathways and regulate the phosphorylation status of a panel of glutamate receptor subunits in the striatum.55 Therefore, studies of PDE10 inhibitors are expected to target both dopaminergic and glutamatergic dysfunction in schizophrenia.

Several PDE10A inhibitors are currently investigated, including TAK-063 and MK-8189 for total schizophrenia symptoms.

**Sodium nitroprusside (nitric oxide donor)**

Nitric oxide may be implicated in the pathophysiology of schizophrenia, as it is a gas that mediates the release of neurotransmitters, and seems to be involved in learning, memory, and neurodevelopment.59 As a nitric oxide donor, sodium nitroprusside may thus improve symptoms of schizophrenia.

The original randomized, double-blind, placebo-controlled study of sodium nitroprusside, conducted in Brazil, examined the effectiveness and safety of a single intravenous administration of sodium nitroprusside (0.5 μg/kg/min for 4 hours) for the improvement of positive, negative, anxiety, and depressive symptoms in 20 patients with schizophrenia who were within the first 5 years of schizophrenia and who were taking antipsychotics.60 After the adjunctive infusion of sodium nitroprusside, a rapid improvement of symptoms was observed within 4 hours, with significant superiority of sodium nitroprusside vs. placebo on the 18-item Brief Psychiatric Rating Scale total score and subscale scores, which persisted for 4 weeks after infusion (Table 2).66

However, three recent studies were unable to replicate these original study results. In one study, 42 adults with schizophrenia were randomized to two placebo or sodium nitroprusside infusions (0.5 μg/kg per min for 4 h) during a 1-week interval.61 The authors failed to find any significant effect of sodium nitroprusside vs. placebo on psychotic symptoms or cognitive functions, although sodium nitroprusside seemed relatively well tolerated. In a second study, 20 patients with a diagnosis of schizophrenia or schizoaffective disorder were randomized to an infusion of sodium nitroprusside (0.5 μg/kg per min for 4 h) or placebo and reassessed for symptoms and cognitive performance immediately after the infusion, and 4 weeks later (Table 2).62 Similarly, the authors failed to observe any significant advantage of sodium nitroprusside vs.
placebo for reducing psychotic symptoms or improving spatial working memory vs. placebo. Finally, in a third, 2-week acute treatment study, patients \( n = 52 \) were randomized to one of three treatment sequences (sodium nitroprusside + sodium nitroprusside; placebo + sodium nitroprusside; placebo + placebo), without separation of sodium nitroprusside from placebo in this study (Table 2). Consistent with the results of the two prior studies, no differences emerged in safety or tolerability measures. However, as in the original, positive study patients were younger, in an earlier illness phase and more severely ill than in the negative trials, patient features that may enhance the efficacy of sodium nitroprusside may need to be considered in future trials.

**Trace amine-associated receptor 1 (TAAR-1) agonists**

Trace amine-associated receptor 1 (TAAR1) is a G-protein-coupled receptor that belongs to the TAAR family. Discovered in 2001, TAARs have been found in several tissues, including the central nervous system and olfactory epithelium. TAAR1 is activated by endogenous trace amines that are structurally related to monoaminergic neurotransmitters. TAAR1 agonists include amphetamine and methamphetamine, and TAAR1 seems to be most selective to dopamine, being less responsive to the endogenous tryptamine, norepinephrine, and serotonin, although glutamatergic transmission may also be modulated. In turn, these receptor features make TAAR1 agonists attractive targets for the treatment of schizophrenia. Currently two TAAR1 agonists are being evaluated for schizophrenia. These include SEP-363856 and RO5263397 (for which wide variations in blood levels have been described based on genotype and ethnicity).

While for RO5263397, phase-II study results have to our knowledge not been publicly reported, results of a phase-Ib study of SEP-363856 have been presented as a poster. In a phase-II, randomized, double-blind, placebo-controlled 4-week, flexible dose study, SEP-363856 50 mg/day or 75 mg/day \( (n = 120) \) was superior to placebo \( (n = 125) \) for PANSS total scores, PANSS positive, PANSS negative, and PANSS general psychopathology subscale score, CGI-S, Brief Negative Symptom Scale (BNSS), and the Montgomery-Asberg Depression Rating Scale (MADRS). All-cause discontinuation (approximately 20%) and intolerability-related discontinuation (10%) were similar to placebo (Table 2). Moreover, changes in body weight, blood glucose, lipids, and prolactin levels were comparable to placebo. Adverse effects \( ≥2\% \) and at a maximum 1-2.5% greater than with placebo included somnolence, nausea, diarrhea, and dyspepsia.

**Negative symptoms**

After a positive phase-II study, the bitopertin program of a GLYT-1 inhibitor was stopped due to following negative studies, leaving again negative symptoms a highly desirable and sorely needed indication for the treatment of schizophrenia. Several different agents are currently investigated for this indication.

**LuAF-11167**

Since PDE10A inhibitors have not reliably separated from placebo in acutely exacerbated schizophrenia, LuAF-11167 is currently being developed for the treatment of negative symptoms. Since, possibly, dopamine blockade due to accompanying antipsychotic treatment in the adjunctive trial programs for acutely exacerbated schizophrenia patients may interfere with the optimized effects of a PDE10A inhibitor for negative symptoms, an ongoing study evaluates LuAF-11167 in monotherapy vs. placebo. Results are not available for this phase-II study.

**Pimavanserin**

Pimavanserin is a 5-HT\(_{2A}\) inverse agonist approved for the treatment of psychosis associated with Parkinson’s disease. In one prior study of schizophrenia patients, pimavanserin added to lower risperidone doses (2 mg/day) was equally efficacious as higher risperidone doses (6 mg/day); also pimavanserin augmentation seemed to reduce EPS. Currently, the ongoing ADVANCE study is a phase-II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adjunctive pimavanserin for the treatment of negative symptoms of schizophrenia. This 26-week study compares three doses of pimavanserin (34 mg, 20 mg, or 10 mg) plus background antipsychotic vs. placebo plus background antipsychotic, with the primary outcome measure being the Negative Symptom Scale-16 (NSA-16). Results are expected later in 2019.

**Roluperidone (MIN-101)**

Roluperidone, also known as MIN-101, is a cyclic amido derivative, with affinities for sigma-2, 5-HT\(_{2A}\), and alpha1-adrenergic receptors, developed to target negative symptoms and cognitive dysfunction in schizophrenia patients. MIN-101 has low affinity for dopaminergic, muscarinic, cholinergic, and histaminergic receptors. Recent studies have shown that MIN-101 is an antagonist at sigma-2 and 5-HT\(_{2A}\).

Reportedly, an unpublished phase-IIa study was positive for negative symptoms in schizophrenia, which was replicated in a phase-Ib trial. In that 12-week study, 234 patients who had been symptomatically stable for at least 3 months and who had predominant negative
symptoms (score ≥20 on the PANSS negative subscale, baseline mean = 26.8) were randomized to roluperidone 32 mg/day or 64 mg/day or placebo. At 12 weeks, MIN-101 32 mg/day and 64 mg/day were statistically significantly superior in the PANSS negative factor score (pentagonal structure model). In addition, positive results were also reported for PANSS negative symptom, total, and activation factor scores, CGI-S, and the BNSS (Table 3). In addition, roluperidone was safe, without clinically significant changes in vital signs, routine laboratory values, body weight, metabolic parameters, or neuromotor scale scores. Adverse events included headache, anxiety, insomnia, schizophrenia symptoms, asthenia, nausea, and somnolence.

Results of secondary analyses from this trial also suggested that roluperidone may also have an enhancing effect on cognitive functioning. The BACS token motor, verbal fluency, and composite z scores improved significantly vs. placebo in the 32 mg roluperidone group, but not the 64 mg/day group, although the efficacy for negative symptoms was greater for the higher dose, and although negative correlations were seen for improvements in certain cognitive symptom domains and negative symptom reduction even in the 64 mg/day group (Table 3). Thus, it is important to note that dose-related effects of roluperidone diverged between negative and cognitive symptom improvement. Moreover, results do not yet indicate whether similar results would be observed for patients with a different range of schizophrenia symptoms. Nevertheless, roluperidone represents an innovative mechanism of action, which seems to be promising in improving the treatment of negative symptoms, as well as cognitive dysfunction while having a favorable safety profile. The ongoing phase-III trial program will have to confirm these initial results.

**TAK-831**

D-serine is an endogenous ligand for the glycine modulatory binding site on the NR1 subunit of NMDA receptors in the brain, whose agonist functioning is thought to improve negative symptoms of schizophrenia. Since D-serine is degraded by the flavoenzyme DAAO, DAAO inhibitors may improve NMDA functioning and negative symptoms in schizophrenia.

TAK 831 is an oral, highly selective and potent DAAO inhibitor that is undergoing phase-II testing for the treatment of negative symptoms in schizophrenia. In this 12-week, placebo-controlled trial, three different doses (50 mg/day, 125 mg/day, 500 mg/day) are tested using the PANSS negative symptoms factor score as the primary outcome.

**Cognitive impairment**

Since the negative results for encenicline, an alpha-7 nicotinic acetylcholine receptor agonist for cognition, in schizophrenia, activity in this area has slowed down considerably. Since glycine is involved in glutamatergic NMDA transmission, which seems to be relevant for both negative and cognitive symptoms in schizophrenia, GLYT-1 agonists may also improve cognitive dysfunction.

**BI-425809**

BI 425809 is a GLYT-1 inhibitor that was well tolerated in a phase-1 study in healthy male volunteers, displaying an adverse event profile suggestive of GLYT1-inhibiting effects. BI 425809 is currently undergoing phase 2 testing for cognitive dysfunction in schizophrenia. In this 12-week, placebo-controlled study, four doses of once daily oral BI 425809 are evaluated for their effect on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) total score, with everyday functional capacity, measured by Schizophrenia Cognition Rating Scale (SCoRS), being the key secondary outcome.

Another 12-week, phase-II, placebo-controlled proof of concept study with the same outcomes is being planned that aims to explore the effect of oral once daily BI 425809 on cognition administration in patients with schizophrenia on stable antipsychotic treatment and adjunctive computerized cognitive training.

**Cannabidiol**

Cannabidiol has also been investigated for the treatment of cognitive dysfunction in schizophrenia. In a 6-week, randomized, placebo-controlled, fixed-dose study targeting cognition, oral cannabidiol (600 mg/day) added on to background antipsychotics was not superior to placebo in 36 stable chronic schizophrenia patients on either the MATRICS CCB or the PANSS total score (Table 3). Similarly, in another 6-week study of 88 patients with schizophrenia focusing on total PANSS that separated on positive symptoms and CGI-I and CGI-S, there was no significant benefit of adjunctive cannabidiol (1000 mg/day) for the secondary outcome of cognition measured with the Brief Assessment of Cognition in Schizophrenia.

**Residual and treatment-resistant positive symptoms**

Residual and refractory symptoms of schizophrenia remain a major unmet need in schizophrenia. Only clozapine is indicated for this indication, and few agents are being studied in this area.

**LuAF-35700**

LuAF-35700 is a D₁-preferring D₁ and D₃ antagonistic investigational antipsychotic agent that is also an antagonist at serotonin 5-HT₂A and 5-HT₆ receptors with high
| References                          | Total n | Trial duration | Active group(s)                                                                 | Comparison(s) groups | Results | Comments                                                                 |
|------------------------------------|---------|----------------|-------------------------------------------------------------------------------|---------------------|---------|--------------------------------------------------------------------------|
| LuAF-11167 47                      | 47      | N/Av           | LuAF-11167 0.25 mg/day (n = N/Av)                                             | Placebo (n = N/Av)  | N/Av    |                                                                          |
| LuAF-11167 0.5 mg/day (n = N/Av)    |         |                |                                                                               |                     |         |                                                                          |
| LuAF-11167 1 mg/day (n = N/Av)      |         |                |                                                                               |                     |         |                                                                          |
| Part A: monotherapy                |         |                |                                                                               |                     |         |                                                                          |
| Part B: adjunctive therapy to       |         |                |                                                                               |                     |         |                                                                          |
| risperidone                         |         |                |                                                                               |                     |         |                                                                          |
| Placebo                            | 380     | 26 weeks       | Pimavanserin 34 mg/day + background antipsychotic (n = N/Av)                  | Placebo (n = N/Av)  | N/Av    |                                                                          |
| Pimavanserin 20 mg/day (n = N/Av)   |         |                |                                                                               |                     |         |                                                                          |
| Pimavanserin 10 mg/day (n = N/Av)   |         |                |                                                                               |                     |         |                                                                          |
| Davidson et al. (2017)78            | 234     | 12 weeks       | Roluperidone 32 mg/day (n = 76)                                               | Placebo (n = 79)    | N/Av    | Positive study: Roluperidone was significantly superior to placebo on   |
| Roluperidone (MIN-101)              |         |                | Roluperidone 64 mg/day (n = 79)                                               |                     |         | the PANSS negative factor score (pentagonal structure model). In addition,|
| Keefe et al. (2018)77               | 234     | 12 weeks       | Roluperidone 32 mg/day (n = 76)                                               | Placebo (n = 79)    |         | positive results were reported for secondary outcomes (PANSS negative,   |
|                                    |         |                | Roluperidone 64 mg/day (n = 79)                                               |                     |         | total and activation factor score, CGI-S, and BNSS). No difference in   |
|                                    |         |                |                                                                               |                     |         | PANSS positive or depression scores.                                      |
|                                    |         |                | PANSS negative (pentagonal structure: N1-N4; G5-G8; G13-14)                   | Roluperidone 32 vs. placebo: p < .024, effect size = .45       |         | Positive secondary analyses of the primary study: results suggest a      |
|                                    |         |                |                                                                               | Roluperidone 64 vs. placebo: p < .004, effect size = .57        |         | possible benefit of roluperidone on cognitive functioning in patients   |
|                                    |         |                |                                                                               |                     |         | with stable positive and concurrent clinically significant negative       |
|                                    |         |                |                                                                               |                     |         | symptoms.                                                                |
|                                    |         |                | BACS Subscale: Tower of London z-score = −1.1, p = .57                       | Roluperidone 64 mg z-score = −1.4, p = .57                   |         |                                                                          |
| References | Total n | Trial duration | Active group(s) | Comparison(s) groups | Results | Comments |
|------------|---------|---------------|----------------|----------------------|---------|----------|
| Token Motor | Roluperidone 32 mg | z-score = −1.1, \( p = .04 \) | Roluperidone 64 mg | z-score = −1.0, \( p = .08 \) |
| Symbol coding | Roluperidone 32 mg | z-score = −2.6, \( p = .77 \) | Roluperidone 64 mg | z-score = −2.7, \( p = .08 \) |
| Verbal fluency | Roluperidone 32 mg | z-score = −1.3, \( p = .01 \) | Roluperidone 64 mg | z-score = −1.2, \( p = .06 \) |
| Verbal memory | Roluperidone 32 mg | z-score = −1.4, \( p = .09 \) | Roluperidone 64 mg | z-score = −1.3, \( p = .09 \) |
| Digit sequency | Roluperidone 32 mg | z-score = −1.3, \( p = .06 \) | Roluperidone 64 mg | z-score = −2.1, \( p = .02 \) |
| BACS composite | Roluperidone 32 mg | z-score = −2.8, \( p = .05 \) | Roluperidone 64 mg | z-score = −2.9, \( p = .72 \) |

(Continued)
| References                  | Total n | Trial duration | Active group(s)                                                                 | Comparison(s) groups         | Results                  | Comments                                                                 |
|----------------------------|---------|----------------|-------------------------------------------------------------------------------|------------------------------|--------------------------|--------------------------------------------------------------------------|
| **TAK-831**                 | 234     | 12 weeks       | TAK-831 50 mg/day *(n = N/Av)*  
TAK-831 125 mg/day *(n = N/Av)*  
TAK-831 500 mg/day *(n = N/Av)* | Placebo *(n = N/Av)*              | PANSS negative              | N/Av                      | N/Av                                                                     |
| [https://clinicaltrials.gov/ct2/show/NCT03382639](https://clinicaltrials.gov/ct2/show/NCT03382639) |         |                |                                                                               |                              |                          |                                                                           |
| **Target: cognitive dysfunction** |         |                |                                                                               |                              |                          |                                                                           |
| **BI-425809**               | 504     | 12 weeks       | BI-425809 4 dosing options *(no further details) *(n = N/Av)*               | Placebo *(n = N/Av)*         | MATRICS SCoRS            | N/Av                      | N/Av                                                                     |
| [https://clinicaltrials.gov/ct2/show/NCT02832037](https://clinicaltrials.gov/ct2/show/NCT02832037) |         |                |                                                                               |                              |                          |                                                                           |
| **https://clinicaltrials.gov/ct2/show/NCT03859973** | 200     | 12 weeks       | BI-425808 3 dosing options *(no further details) + Adjunctive Computerized Cognitive Training *(n = N/Av)* | Placebo + Adjunctive Computerized Cognitive Training *(n = N/Av)* | MATRICS SCoRS PANSS     | N/Av                      | N/Av                                                                     |
| Cannabidiol                 |         |                |                                                                               |                              |                          |                                                                           |
| Boggs et al. (2018)⁹⁹       | 36      | 6 weeks        | Cannabidiol 600 mg/day + preexisting antipsychotic *(n = 18)*                | Placebo + preexisting antipsychotic *(n = 18)* | MATRICS composite Score | *F*(1,32) = 1.48, *p* = .23 | Negative study: Cannabidiol was not significantly superior to placebo in enhancing cognitive functioning or PANSS total score. |
| McGuire et al. (2018)⁹⁶     | 88      | 6 week         | Cannabidiol 1000 mg/day + preexisting antipsychotic *(n = 43)*               | Placebo + preexisting antipsychotic *(n = 45)* | PANSS total BACS | *F*(3,101) = 1.66, *p* = .18  
Treatment difference: 1.31; 95% CI = -.10, 2.72; *p* = .068 | Negative study: Cannabidiol was not significantly superior to placebo on the BACS. |

BACS, Brief Assessment of Cognition in Schizophrenia; CI, confidence interval; MATRICS, Measurement and Treatment Research to Improve Cognition in Schizophrenia; PANSS, Positive and Negative Syndrome Scale; SCoRS, Schizophrenia Cognition Rating Scale.
alldem- and safe at both doses.91 Currentl}, this novel antipsychotic is in phase-III of its clinical development, evaluating two doses (10 mg/day and 20 mg/day) in the Daybreak99 and one dose (10 mg/day) in the ANEW90 study programs.

In the DAYBREAK study, 1098 patients who had failed at least one prior well-documented antipsychotic treatment trial without satisfactory clinical improvement were enrolled and underwent a single-blinded, prospective, 6-week treatment period with either risperidone (4-6 mg/day) or olanzapine (15-20 mg/day) to confirm antipsychotic treatment resistance. Those failing to adequately respond to prospective treatment with risperidone or olanzapine were randomized to either stay on this treatment or switch to LuAF-35700 for another 10 weeks. In a press release from on October 25, 2018, Lundbeck announced that in the DAYBREAK study LuAF-35700 was not superior, but as effective as olanzapine or risperidone for treatment-resistant patients (Table 4). The drug was well tolerated and safe at both doses.91

Due to these results, the ANEW was terminated that had a similar design, except for evaluating a single dose of 10 mg/day of LuAF-35700 vs. placebo and for stratifying randomization for treatment-resistant schizophrenia developing either within the first 5 years or after 10 years of the illness. Final results in a relatively small number of randomized patients are currently awaited.

**Pimavanserin**

Since a first augmentation study of risperidone with pimavanserin had shown that enhancing 5-HT2A receptor blockade by adding pimavanserin to a sub-effective risperidone dose provided faster onset of action, and at endpoint, equal efficacy and better safety, compared to standard dose risperidone, while reducing EPS, a program for schizophrenia patients with suboptimal positive symptom response was initiated.

The recently completed ENHANCE-1 study is a phase-III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adjunctive pimavanserin for the treatment of schizophrenia with residual positive symptoms.92 This international, 6-week study (n = 396, mean age = 37.2 years) compared pimavanserin (starting dose 20 mg, with adjustments possible to 34 mg or 10 mg) plus background antipsychotic vs placebo plus background antipsychotic (risperidone = 39.1%, olanzapine = 55.7%, aripiprazole = 21.3%).93 Despite numerical advantages, pimavanserin augmentation missed statistical separation from placebo for the primary outcome, PANSS total score (p = 0.0940). A positive trend was also observed on the key secondary endpoint, the CGI-S score (p = 0.0543). In a pre-specified subgroup analysis by region, significant separation from placebo was seen in the European sites (>80% of the sample) both for the PANSS total score (unadjusted p = 0.0234), and the CGI-S score (unadjusted p = 0.0214). Furthermore, in the entire sample, pimavanserin reduced negative symptoms significantly more than placebo, both regarding the PANSS negative symptoms scale sub-score (unadjusted p = 0.0474) and the PANSS Marder negative factor score (unadjusted p = 0.0362).

Approximately 88% of pimavanserin and 96% of placebo patients completed the study. Additionally, pimavanserin was well-tolerated with low and similar rates of adverse events in the adjunctive pimavanserin (40.4%) and adjunctive placebo (36.9%) groups. Adverse events reported in at least 5% of patients in the pimavanserin group included headache, somnolence, and insomnia. Discontinuations due to adverse effects were low, being 2.5% for pimavanserin vs. 0% for placebo.93

**Sodium benzoate**

Not only dopaminergic hyperactivity but also NMDA receptor hypofunction has been implicated in the pathophysiology of schizophrenia, possibly especially in patients resistant to treatment with dopamine antagonizing agents.33 In addition to NMDA partial or full agonists, NMDA functioning can be increased by raising d-amino acid levels via blockade of their metabolism. Sodium benzoate, a DAAO inhibitor and common food preservative, has this mechanism. In two placebo-controlled trials, sodium benzoate had beneficial efficacy and acceptable tolerability.94,95

In the first randomized, double-blind, placebo-controlled trial, 52 patients with chronic schizophrenia stabilized with antipsychotics for ≥3 months were randomized to 6 weeks of add-on treatment of 1 g/day of sodium benzoate vs. placebo. Sodium benzoate produced a 21% improvement in PANSS total score, and with large effect sizes (range = 1.16-1.69). Sodium benzoate was significantly superior to placebo in the PANSS total and subscales, Scales for the Assessment of Negative Symptoms-20 items, Global Assessment of Function, Quality of Life Scale and Clinical Global Impression. In addition, neurocognition subtests improved significantly, including the domains of processing speed and visual learning (Table 4). Sodium benzoate was well tolerated without significant adverse effects.

In the second randomized, double-blind, placebo-controlled trial, 60 inpatients with schizophrenia stabilized with clozapine were randomized to 6 weeks of add-
| References | Total \( N \) | Trial duration | Active Group(s) | Comparison(s) Groups | Results | Comments |
|------------|--------------|----------------|----------------|----------------------|---------|----------|
| LuAF-35700 | 1098         | 16-weeks       | LuAF-35700 10mg/day \((n = N/Av)\) | Risperidone 4-6mg/day \((n = N/Av)\) | PANSS total N/Av | Negative study: LuAF-35700 was not superior to, but as effective as risperidone and olanzapine. |
|            |              |                | LuAF-35700 20mg/day \((n = N/Av)\) | Olanzapine 15-20mg/day \((n = N/Av)\) |         |          |
|            | 120          | 14-weeks       | LuAF-35700 10mg/day \((n = N/Av)\) | Risperidone 4-6mg/day \((n = N/Av)\) | PANSS total N/Av | N/Av |
| Pimavanserin | 396          | 6-weeks        | Pimavanserin 10mg, 20mg or 34mg/day + background antipsychotic \((n = 193)\) | Placebo + background antipsychotic \((n = 196)\) | PANSS total \( p = .0940 \) (European subsample, \( >80\% \); unadjusted \( p = .0234 \)) | Negative study for the primary outcome, but trend-level significance in the entire sample as well as positive study in the preplanned subgroup analysis of the European sites (approx. 80% of the sample), both for PANNS total and for CGI-S. Also, significant separation from placebo for negative symptoms in the entire sample. |
|            |              |                |                | CGI-S \( p = .0543 \) (European subsample, \( >80\% \); unadjusted \( p = .0214 \)) | unadjusted \( p = 0.474 \) |          |
|            |              |                |                | PANSS Negative Factor Score |         |          |
| Sodium Benzoate | 52          | 6-weeks        | Sodium Benzoate 1000mg/day \((n = 25)\) | Placebo \((n = 27)\) | PANSS total Treatment difference \((SE) = -2.1 (0.3); p < .001, effect size = 1.53\) | Positive study: Sodium benzoate was significantly superior to placebo on the PANSS total score, PANSS subscales, SANS, GAF, QOLS, CGI, and cognitive functioning. |
|            |              |                |                | PANSS positive Treatment difference \((SE) = -0.6 (0.1); p < .001, effect size = 1.69\) |         |          |
|            |              |                |                | PANSS negative Treatment difference \((SE) = -0.6 (0.1); p < .001, effect size = 1.19\) |         |          |
|            |              |                |                | PANSS general Treatment difference \((SE) = -0.9 (0.2); p < .001, effect size = 1.16\) |         |          |
|            |              |                |                | SANS Treatment difference \((SE) = -2.0 (0.2); p < .001, effect size = 1.56\) |         |          |
|            |              |                |                | GAF Treatment difference \((SE) = 1.1 (0.2); p < .001, effect size = 1.2\) |         |          |
|            |              |                |                | QOLS Treatment difference \((SE) = 1.1 (0.2); p < .001, effect size = 1.5\) |         |          |
|            |              |                |                | CGI-???? Treatment difference \((SE) = -0.1 (0.02); p < .001, effect size = 1.21\) |         |          |
|            |              |                |                | HDRS Treatment difference \((SE) = -0.13 (0.1); p < .001, effect size = 0.74\) |         |          |
|            |              |                |                | Speed of Processing \( p = .03, effect size = .65\) |         |          |
|            |              |                |                | Verbal learning and memory \( p = .02, effect size = .07\) |         |          |
|            |              |                |                | Neurocognitive composite \( p = .04, effect size = .67\) |         |          |
| References       | Total N | Trial duration | Active Group(s)                      | Comparison(s) Groups          | Results                                                                 | Comments                                                                 |
|------------------|---------|----------------|--------------------------------------|------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Lin et al., 2018 | 60      | 6-weeks        | Sodium Benzoate 1g/day (n = 20)      | Placebo (n = 20)              | Sodium Benzoate 1g/day vs. placebo Treatment difference (SE) = −3.35   | Positive study: Sodium benzoate was significantly superior to placebo on the PANSS total score PANSS subscales and QOLS, but mainly for the sodium benzoate 2g group only. |
|                  |         |                | Sodium Benzoate 2g/day (n = 20)      |                              | (2.38); p = .159                                                       |                                                                          |
|                  |         |                |                                      |                              | Sodium Benzoate 2g/day vs. placebo Treatment difference (SE) = −3.80   |                                                                          |
|                  |         |                |                                      |                              | (1.35); p = .005                                                       |                                                                          |
|                  |         |                |                                      | PANSS total                  | Treatment difference (SE) = −3.35                                      |                                                                          |
|                  |         |                |                                      | PANSS positive               | Treatment difference (SE) = −0.59 (.70); p = .401                     |                                                                          |
|                  |         |                |                                      | SANS                        | Treatment difference (SE) = −3.90 (1.73); p = .024                    |                                                                          |
|                  |         |                |                                      | QOLS                        | Treatment difference (SE) = 2.70 (1.53); p = .078                     |                                                                          |
|                  |         |                |                                      | GAF                         | Treatment difference (SE) = 1.50 (1.03); p = .147                    |                                                                          |
| CGI = Clinical Global Impressions Scale; GAF = Global Assessment of Functioning; HDRS = Hamilton Depression Rating Scale; PANSS = Positive and Negative Syndrome Scale; N/Av = Not Available; QOLS = Quality of Life Scale; SANS = Scale for the Assessment of Negative Symptoms; SE = Standard Error |
on treatment with 1 g/day sodium benzoate, 2 g/day sodium benzoate, or placebo. At 6 weeks, 2 g/day sodium benzoate was associated with significantly greater improvement than placebo in PANSS total score, PANSS positive subscore, and Quality of Life Scale. Furthermore, both the 1 mg/day and 2 mg/day sodium benzoate were associated with significantly greater improvement in the Scale for the Assessment of Negative Symptoms vs. placebo (Table 4). Sodium benzoate was well tolerated without relevant adverse effects. Furthermore, as an indication of the mechanism involved in the significant results, changes of the antioxidant catalase differed among the three groups and were correlated with the improvement of PANSS total score and PANSS positive score in the sodium benzoate group.

**Agents targeting antipsychotic non-adherence**

Non-adherence remains a serious issue with schizophrenia as with many other psychiatric and medical disorders. Although several second-generation LAIs have been approved, several have required oral cotreatment for several weeks until therapeutic antipsychotic levels have been reached. Moreover, historically, all LAIs were injected deep intramuscularly. Four innovative LAI formulations have been developed to avoid the need for loading or booster injections and/or oral cotreatment. Furthermore, two LAI formulations have received recent FDA approval, one being the first subcutaneously injected LAI.

**Aripiprazole lauroxil NanoCrystal® Dispersion (ALNCD; Aristada Initio)**

Aripiprazole lauroxil (AL) (Aristada®) is an extended-release, intramuscular long-acting injectable (LAI) aripiprazole prodrug with high dosage and considerable dosing interval flexibility (441, 662, and 882 mg monthly; 882 mg every 6 weeks, or 1064 mg every 8 weeks). However, due to being a prodrug and slow release, therapeutic drug levels are achieved only gradually, so that oral aripiprazole supplementation for 21 consecutive days is required after the first intramuscular injection.

In order to achieve faster efficacy and significantly shorten or eliminate oral supplementation during the initiation phase, a 1-day intramuscular initiation regimen for aripiprazole lauroxil (Aristada®) was approved by the FDA on July 2, 2018. The single injection comprises the same prodrug used in aripiprazole lauroxil but with smaller particles, known as the nanocrystalline milled dispersion of aripiprazole lauroxil. The smaller nanoparticle size enables faster dissolution of aripiprazole lauroxil, resulting in faster release of aripiprazole into plasma. Simultaneous administration of the 1-day initiation regimen with all approved aripiprazole lauroxil dosing regimens is predicted to achieve the correct blood levels within 4 days.

A recent phase-III, double-blind, placebo-controlled study compared a 1-day initiation regimen with the 21-day oral coverage regimen. Patients (n = 161) randomized to the 1-day initiation regimen received a 675 mg injection of aripiprazole lauroxil NanoCrystal® Dispersion (ALNCD), a single 30 mg oral aripiprazole tablet, and then an aripiprazole lauroxil injection (441 mg or 882 mg). Subjects randomized to the 21-day oral coverage regimen received 15 mg oral aripiprazole and an aripiprazole lauroxil injection (441 mg or 882 mg) on day 1, followed by 20 days of 15 mg oral aripiprazole. The 1-day regimen groups had comparable aripiprazole exposure to the corresponding 21-day groups (Table 5). The most common side effects were injection pain, headache, weight gain, insomnia, dyspepsia, and anxiety in both therapies.

Therefore, aripiprazole lauroxil NanoCrystal Technology can offer an alternative aripiprazole lauroxil initiation regimen that ensures therapeutic aripiprazole levels during the first 21 days of treatment and has a comparatively side effect profile, faster efficacy, and might positively affect adherence due to a very minimized (1 day) oral supplementation.

**Paliperidone 6-monthly formulation**

After developing a once-monthly and a 3-monthly intramuscular injectable formulation of paliperidone, Janssen is currently conducting phase III trial for a 6-monthly formulation of paliperidone palmitate. Results are still outstanding.

**Perseris™ risperidone for subcutaneous injection (RBP-7000)**

Risperidone has been available since 1993 to treat schizophrenia and bipolar disorders. Risperidone blocks serotonergic 5-HT2A and dopaminergic D2 receptors with greater affinity to the 5-HT2A receptor. In addition, there is a much less affinity to other receptors such as alpha-1- and alpha-2-adrenergic receptors as well as H1-histaminergic receptors. Up until 2018, risperdone LAI was only available in a microsphere formulation that had to be injected deep intramuscularly every 2 weeks and that required a 21-day oral risperidone supplementation phase at the initiation of risperidone microsphere treatment.

RBP-7000 (Perseris™) is a recently (July 27, 2018) FDA-approved subcutaneous LAI formulation of risperidone that requires no oral supplementation and is the first antipsychotic available as a subcutaneously (intraabdominally) administered LAI. The once monthly injected depot formulation uses the ATRIGEL® administration system. After injection, the delivery system solidifies upon contact with bodily fluids, and the
### TABLE 5. Selected novel and emerging pharmacological treatments for schizophrenia targeting the amelioration of antipsychotic non-adherence and body weight gain

| References                  | Total N | Trial duration | Active group(s)                                      | Comparison(s) groups | Results                                                                 | Comments |
|-----------------------------|---------|----------------|------------------------------------------------------|----------------------|-------------------------------------------------------------------------|----------|
| **Aripiprazole Lauroxil (AL) NanoCrystal® Dispersion (Aripiprazole Lauroxil NCD; Aristada Initio)** | 161     | 3 weeks        | AL 441 mg/1-day (n = 39) AL 882 mg/1-day (n = 41) | AL 441 mg/21-days (n = 40) AL 882 mg/21-days (n = 41) | N/A N/A | Positive study: The 1-day regime groups had comparable aripiprazole exposure to the corresponding 21-day group. |
| **Risperidone ISM® (Doria®)** | 438     | 12 weeks       | Risperidone ISM 75 mg/day (n = N/Av) Risperidone ISM 100 mg/day (n = N/Av) | Placebo (n = N/Av) | PANS total Risperidone ISM 75 mg vs. placebo p < .0001 Risperidone ISM 100 mg vs. placebo p < .0001 | Positive study: Risperidone was significantly superior to placebo in PANS total and CGI-S scores. |
| **Perseris™ Risperidone (RBP-7000)** | 337     | 8 weeks        | RBP-7000 90 mg/day (n = 111) RBP-7000 120 mg/day (n = 114) | Placebo (n = 112) | PANS total RBP-7000 90 mg vs. placebo p = .0004 RBP-7000 120 mg vs. placebo p < .0001 RBP-7000 90 mg vs. placebo, p = .186 RBP-7000 120 mg vs. placebo, p = .039 | Positive study: RBP-7000 was significantly superior to placebo on the PANS total, positive, and general score, as well as on the CGI-S. RBP-7000 was not superior to placebo on the PANS negative subscale score. |

(Continued)
| References     | Total N | Trial duration | Active group(s)                                                                 | Comparison(s)           | Results                                      | Comments                                                                 |
|---------------|---------|----------------|------------------------------------------------------------------------------|-------------------------|---------------------------------------------|--------------------------------------------------------------------------|
| **Target: amelioration of adverse effects**<br>Samidorphan + olanzapine (ALKS3831)** | **309** | **6 weeks** | Samidorphan 5 mg/day + olanzapine (n = 80)<br>Samidorphan 10 mg/day + olanzapine (n = 86)<br>Samidorphan 20 mg/day + olanzapine (n = 68) | Placebo + olanzapine (n = 75) | Body weight<br>Samidorphan 5 mg vs. placebo 2.8% vs. 4.1%<br>Samidorphan 10 mg vs. placebo 2.1% vs. 4.1%<br>Samidorphan 20 mg vs. placebo 2.9% vs. 4.1% | **Positive study:** Samidorphan was superior to placebo in reducing olanzapine-induced weight gain. |
| Martin et al. (2018)** | **403** | **4-weeks** | ALKS3831 (n = 266)<br>ALKS3831 (n = N/Av) | Olanzapine (n = 272)<br>Olanzapine (n = N/Av)<br>Placebo (n = N/Av) | Body weight<br>ALKS3831 vs. olanzapine 4.2% vs. 6.6%, p = .003<br>ALKS3831 vs. placebo, p < .001<br>Olanzapine vs. placebo, p = .004 | **Positive study:** ALKS3831 was significantly superior to placebo in reducing olanzapine-induced weight gain.<br>**Positive study:** ALKS3831 was significantly superior to placebo in reducing PANSS total and CGI-S scores, being almost identical to olanzapine. |
| **ENLIGHTEN-2** | **915** | **12 weeks** | ALKS3831 (n = 458)<br>ALKS3831 (n = N/Av) | Olanzapine (n = 279)<br>Olanzapine (n = N/Av)<br>Placebo (n = N/Av) | Body weight<br>ALKS3831 vs. olanzapine 4.2% vs. 6.6%, p = .003<br>ALKS3831 vs. placebo, p < .001<br>Olanzapine vs. placebo, p = .004 | **Positive study:** ALKS3831 was significantly superior to placebo in reducing olanzapine-induced weight gain.<br>**Positive study:** ALKS3831 was significantly superior to placebo in reducing PANSS total and CGI-S scores, being almost identical to olanzapine. |

CGI-S, Clinical Global Impression Scale – severity; N/Av, not available; PANSS, Positive and Negative Syndrome Scale.
resulting biodegradable implant delivers the drug for a longer period depending on the dose strength and the injection volume.\textsuperscript{105}

Pharmacokinetic population analyses reported optimized occupancy of the dopamine D\textsubscript{2} receptor for RBP-7000 after repeated doses of 90 mg/day and 120 mg/day and a potentially improved side effect profile compared to oral risperidone.\textsuperscript{106,107} An 8-week, pivotal phase-III double-blind, placebo-controlled trial in acutely exacerbated patients with schizophrenia demonstrated the efficacy, safety, and tolerability of RBP-7000 (90 mg/day and 120 mg/day).\textsuperscript{108-110} Common treatment-related side effects were injection site pain, headache, sedation/somnolence, and weight gain. Mean subject-reported injection site pain, as measured by the Visual Analog Scale scores (0 = no pain to 100 = unbearably painful), was similar in all treatment groups following both injections, with pain scores decreasing from a mean of 27 at 1 min after the first dose to a range of 3-7 at 30-60 min postdose. Moreover, de novo patients were recruited, and completers from the double-blind placebo-controlled study were transferred to a 1-year open-label study in which they received monthly injections of RBP-7000 (120 mg/day). In general, the safety achieved with 12 monthly injections of RBP-7000 was comparable to that of oral risperidone (Table 5). In addition, symptoms continued to improve in completers of the placebo-controlled trial who moved on to the long-term study.\textsuperscript{111}

RBP-7000 has fast efficacy without the need for loading or booster injections or oral cotreatment and the subcutaneous injection route, which is hoped to be associated with less injection pain improved convenience, acceptance, and adherence. However, like risperidone microspheres, RBP-7000 needs to be refrigerated; furthermore, it needs to be reconstituted, and a large bore needle (18 G 5/8-inch length needle) is required for the subcutaneous intrabdominal injection.\textsuperscript{104}

**Risperidone extended release for subcutaneous injection (TV-46000)**

Currently, risperidone extended release (TV-46000) is being studied in different dose regimens administered subcutaneously in patients with schizophrenia aged 13-65 years. One placebo-controlled study evaluates the efficacy, safety, and tolerability of two dose regimens of TV-46000 as relapse prevention treatment of patients who are clinically stabilized and eligible for risperidone treatment.\textsuperscript{112} One TV-46000 dose-controlled study evaluates the long-term safety and tolerability of two dose regimens and will last up to 80 weeks (including a 4-week screening period, 12-week oral conversion/stabilization stage, 56-week double-blind maintenance stage, and 8-week follow-up period).\textsuperscript{113} Results are expected in the middle or end of 2020.

**Risperidone ISM\textsuperscript{®} or Doria\textsuperscript{®}**

Recently, positive topline results of the PRISMA-3 trial, a multicenter, randomized, placebo-controlled phase-III study of once-monthly intramuscular Doria\textsuperscript{®} or Risperidone ISM\textsuperscript{®}, were announced.\textsuperscript{114} ISM\textsuperscript{®} is a technology for the release of drugs that is based on the in-situ formation of biodegradable matrices after the administration of a liquid carrier. Due to its special characteristics, therapeutic antipsychotic blood levels are achieved without requirement of initial oral antipsychotic coadministration or initial loading or booster injections. In the PRISMA-3 study\textsuperscript{115} of 438 acutely exacerbated patients with schizophrenia, once-monthly injections of 75 mg and 100 mg of Risperidone ISM\textsuperscript{®} each showed statistically significant improvement (p < .0001) vs. placebo injections in the total score of the PANSS as well as in the CGI-Severity scale at 12 weeks, the pre-specified primary and key secondary efficacy endpoints (Table 5).\textsuperscript{114} A long-term, open label study that evaluates the safety, tolerability, and durability of the long-term effects of Risperidone ISM\textsuperscript{®} is under way.

**Amelioration of antipsychotic-related adverse effects**

The recent FDA approval of the vesicular monoamine transporter-2 (VMAT-2) inhibitors valbenazine and deuterobenzamine for the effective amelioration of tardive dyskinesia associated with antidopaminergic medications in schizophrenia\textsuperscript{116} was the first indication of a novel mechanism molecule specifically for the management of an adverse effect of antipsychotic medications. Currently, ALKS3831 is under study to ameliorate weight gain associated with olanzapine treatment.

**Olanzapine-related weight gain**

Most currently available antipsychotics are associated with considerable weight gain and cardiometabolic adverse effects.\textsuperscript{22,23,117} These adverse effects are relevant for cardiovascular morbidity and mortality,\textsuperscript{27} and are especially prominent early on in treatment and especially with clozapine and olanzapine.\textsuperscript{118-120} Since both clozapine and olanzapine have been associated with efficacy advantages,\textsuperscript{120,121} mitigating the weight gain and/or metabolic burden is of high clinical importance.

**Fixed-dose combination of olanzapine and samidorphan (ALKS3831)**

Samidorphan is an opioid antagonist, which originally has been investigated for the treatment of addiction and which is now examined for its mitigating or preventing effect of olanzapine-induced weight gain. Samidorphan (ALKS33) binds with high affinity to human μ-, k-, and δ-opioid receptors and functionally acts as an μ-opioid receptor antagonist with low intrinsic activity at k- and
δ-opioid receptors. By blocking opioid receptors involved in the brain reward pathway augmentation is decreased and cravings are reduced. Results of a phase-I trial in healthy volunteers indicated that combining olanzapine with samidorphan (ALKS3831) did not affect the pharmacokinetic profile of either drug. Similarly, in a phase-I proof of concept study in healthy volunteers, samidorphan in combination with olanzapine was associated significantly with less weight gain than olanzapine alone. In recent studies, the combination drug ALKS3831 has been investigated, comprising a flexible dose of olanzapine and a fixed dose (10 mg/day) of samidorphan.

Results of a 12-week, phase-II trial (ENLIGHTEN-1) suggested mitigating effects of ALKS3831 on olanzapine-induced weight gain in schizophrenia patients across all dose-ranges of olanzapine, with equivalent efficacy to olanzapine and with a similar safety profile, except for significantly less weight gain. This study had a 1-week open-label olanzapine lead-in period, which was followed by 12 weeks of double-blind treatment with olanzapine plus placebo (n = 75) or olanzapine plus 5 mg (n = 80), 10 mg (n = 86), or 20 mg (n = 68) of samidorphan. Treatment with ALKS3831 was associated with statistically significant lower weight gain (37% lower weight gain vs. olanzapine plus placebo) (Table 5). Adverse events reported at a frequency ≥5% in any of the ALSK3831 groups and occurring at least two times more frequently than with olanzapine plus placebo included somnolence, sedation, dizziness, and constipation. Since all patients received a 1-week olanzapine monotherapy run-in treatment and since olanzapine alters metabolic glucose and lipid parameters within a week, this study was not designed to assess metabolic effects of ALKS3831.

These positive results have recently been replicated in a 6-month study (ENLIGHTEN-2) where ALKS-3831 was associated with statistically significant advantages over olanzapine plus placebo for both primary endpoints, percentage change in body weight at 6 months and proportion of patients gaining ≥10%, as well as for the key secondary endpoint, the proportion of patients gaining ≥7%. At 6 months, weight increased with ALKS3831 (n=266) by 4.21% vs. 6.59% with olanzapine (n=272), translating into a 57% lower mean percent weight change (p=0.003). Similarly, weight gain ≥10% ALKS3831 occurred in 17.8% with ALKS3831 vs. 29.8% for olanzapine (p = .003, number-needed-to-treat (NNT)≈9). Finally, weight gain ≥7% ALKS3831 occurred in 27.5% with ALKS 3831 vs. 42.7% with olanzapine (Table 5). For weight gain ≥2%, ≥5%, and ≥15% at six months, similar results were observed, each favoring ALKS3831. In the ENLIGHTEN-2 study, there was no significant difference between ALKS3831 and olanzapine at the end of 6 months in any of the investigated glucose and lipid metabolism parameters. However, somewhat surprisingly, the mean increases in fasting glucose, insulin, HbA1C and lipids were relatively small, which may have reduced the power to differentiate ALKS 3831 from Olanzapine. The most common adverse events with ALKS3831 were weight gain, somnolence, and dry mouth; the most common adverse events with olanzapine were weight gain, somnolence, and increased appetite.

Finally, in a 4-week, phase-III, randomized, double-blind active (olanzapine monotherapy) and placebo-controlled trial in patients experiencing exacerbation of schizophrenia, ALKS3831 was investigated to demonstrate that addition of the centrally active samidorphan to olanzapine in ALKS3831 does not reduce olanzapine’s efficacy. This study showed superior antipsychotic efficacy of ALKS3831 compared to placebo, with almost identical efficacy as olanzapine monotherapy (Table 5). ALKS3831 was generally well tolerated, with a safety profile similar to olanzapine. Adverse events leading to study discontinuation included weight gain, somnolence, dry mouth, anxiety, headache, and schizophrenia. In this short, 4-week study, body weight gain was not dissimilar between olanzapine and ALKS3831. Nevertheless, the results must be seen within the study’s limitations, including baseline difference between groups with regard to BMI, the acute nature of the study population, inpatient treatment, and a short duration of the trial, making it difficult to compare weight gain between the three groups, as ALKS3831 is known to exert its weight gain mitigating effect only after 3 weeks of treatment.

Overall, ALKS 3831 has proven to be effective in the treatment of schizophrenia and has been associated with significantly less olanzapine-induced weight gain. Questions still remain regarding the potential of ALKS3831 to also mitigate olanzapine’s adverse effects on glucose and lipid parameters, and on oxidative stress and inflammation that are generally associated with significant body weight gain.

Summary and Conclusion

This targeted and selective review (i) differentiated the mechanisms of action of new and emerging antipsychotics and medications with novel mechanisms targeting total, positive, negative, and cognitive symptoms of schizophrenia, as well as residual and treatment-resistant positive symptoms, non-adherence, and olanzapine-related weight gain, and (ii) evaluated the latest clinical data on these agents inasmuch as these are already available. Successful phase-III and/or phase-II trial programs have included (i) new formulations of aripiprazole lauroxil LAI and risperidone LAI that have been able to avoid the need for oral cotreatment, as well as, in the case of the two risperidone LAI formulations, loading/booster...
with the efficacy of novel, non-dopamine receptor targeting agents that focus on the improvement of negative symptoms, two trial programs attempt the testing of monotherapy of a non-dopaminergic mechanism molecular entity. These include the phase-II - PDE-10 inhibitor LuAF-11167 trial program12 and the 5HT2A/sigma 2 antagonist roluperidone (MIN-1010).78 While data from the ongoing phase-II PDE10A inhibitor LuAF-11167 trial program are not available, roluperidone has already shown in one phase-II trial superiority vs. placebo for negative symptoms.78 Although this superiority did not seem to have been accompanied by too many psychotic exacerbations (surprisingly both in the roluperidone and in the placebo arm), despite withdrawal of the antipsychotic for the 3-month study period (plus an up to 4-week washout period), concern remains as to the safety of both roluperidone and LuAF-11167 that may not be sufficiently antipsychotic in and of themselves to protect patients from a psychotic relapse. It will be important to observe longer-term data with each of these agents and to identify characteristics of patients with relevant levels of negative symptoms who could possibly be sufficiently stable to be switched safely to a non-dopamine targeting novel agent. These studies will need to prove that, in fact, such non-dopamine modulating agents can improve negative symptoms while maintaining positive symptom stability, despite the removal of the prior dopamine modulating antipsychotic agent that at one point was needed to reduce schizophrenia symptoms.

Even 66 years after the serendipitous discovery of chlorpromazine as the first “antipsychotic” agent, the most challenging issue in the pharmacological management of this complex and multifactorial disorder is the need for increased efficacy, reduced side effects, and exploring novel approaches to effectively treat negative symptoms, cognitive dysfunction, and residual/treatment-resistant positive symptoms, which currently remain the biggest gaps in the management of schizophrenia.130

Although emerging data exist, results from important trial programs are still outstanding and further high-quality trials are required to evaluate the efficacy and tolerability of novel pharmacological approaches to the management of different domains of schizophrenia. Unfortunately, to date, only limited progress has been made in the exploration of novel psychopharmacological treatment targets for schizophrenia that go beyond the D2 hypothesis. Therefore, the need for novel treatment approaches, which target the entire range of complex symptoms in schizophrenia, remains urgent. Nevertheless, part of the limited success for the search of novel treatments for schizophrenia remains the limited understanding of the pathophysiology of schizophrenia.1 Therefore, a better understanding of pathophysiological mechanism and biomarkers is indispensable to ensure improved drug development for schizophrenia.

The other selectively reviewed agents have had either suggestive or mixed or, even, negative findings, or are at different stages of phase-II or phase-III development for different symptom domains of schizophrenia. Suggestive and encouraging results exist for monotherapy with roluperidone (MIN-101) for negative symptoms,78 and the TAAR1 agonist SEP-363856.71 D3 antagonist/5HT1A partial agonist F17464, cannabidiol, and sodium benzoate for total psychotic symptoms. Negative findings have been reported for total symptom reduction with PDE10A inhibitors (e.g., MK-8189 and TAK-063) and sodium nitroprusside given adjunctively with background antipsychotics in acutely/severely ill patients, for cannabidiol targeting cognitive dysfunction in schizophrenia, and for monotherapy with the D1/D2-antagonist LuAF-35700 for treatment-resistant schizophrenia. The pimavanserin trial for residual positive symptoms was negative for the primary and key secondary outcome in the overall sample, but showed significant separation from placebo in the prespecified regional analysis of the European sites that had enrolled >80% of the sample, and showed significant separation from placebo for negative symptoms in the overall analysis set.93 Relevant data are expected soon for pimavanserin augmentation of antipsychotics for predominant negative symptoms. Trials are under way, but in the early stages for the DAAO inhibitor TAK-831 given adjunctively with antipsychotics and the phosphodiesterase 10A inhibitor LuAF-11167 in monotherapy for negative symptoms, as well as the GLYT-1 inhibitor BI-425809 targeting cognitive dysfunction in schizophrenia.

Of note, the findings of lumateperone showing that the lower 40 mg dose was significantly superior to placebo for positive symptoms and CGI-S, but not for total symptoms,50 suggest that in future studies of novel agents that have minimal adverse effects, the broad-spectrum endpoint of total PANSS may be better exchanged for the more specific PANSS positive subscale when targeting the reduction of psychotic symptoms.

Interestingly, since dopamine blockade of background antipsychotic treatment may possibly interfere

leading to FDA approval of Aripiprazole Lauroxil NanoCrystal® Dispersion (ALNCD; Aristada Initio) and once-monthly subcutaneously injected Perserin® (RBP-7000); (ii) the treatment of acutely exacerbated schizophrenia with lumateperone, a novel antipsychotic modulating dopamine, serotonin and, via D1 agonism, glutamatergic transmission50 that is currently being evaluated by the FDA for approval for acutely exacerbated schizophrenia, and (iii) the combination of samidorphan plus olanzapine in one pill for the reduction of body weight gain with ALKS3831 at 3 and 6 months,123,125,126 while maintaining olanzapine’s efficacy.124,127,128

Injections in the initial phases of LAI treatment,100,111,114 leading to FDA approval of Aripiprazole Lauroxil NanoCrystal® Dispersion (ALNCD; Aristada Initio) and once-monthly subcutaneously injected Perserin® (RBP-7000); (ii) the treatment of acutely exacerbated schizophrenia with lumateperone, a novel antipsychotic modulating dopamine, serotonin and, via D1 agonism, glutamatergic transmission50 that is currently being evaluated by the FDA for approval for acutely exacerbated schizophrenia, and (iii) the combination of samidorphan plus olanzapine in one pill for the reduction of body weight gain with ALKS3831 at 3 and 6 months,123,125,126 while maintaining olanzapine’s efficacy.124,127,128

Injections in the initial phases of LAI treatment,100,111,114 leading to FDA approval of Aripiprazole Lauroxil NanoCrystal® Dispersion (ALNCD; Aristada Initio) and once-monthly subcutaneously injected Perserin® (RBP-7000); (ii) the treatment of acutely exacerbated schizophrenia with lumateperone, a novel antipsychotic modulating dopamine, serotonin and, via D1 agonism, glutamatergic transmission50 that is currently being evaluated by the FDA for approval for acutely exacerbated schizophrenia, and (iii) the combination of samidorphan plus olanzapine in one pill for the reduction of body weight gain with ALKS3831 at 3 and 6 months,123,125,126 while maintaining olanzapine’s efficacy.124,127,128

Injections in the initial phases of LAI treatment,100,111,114 leading to FDA approval of Aripiprazole Lauroxil NanoCrystal® Dispersion (ALNCD; Aristada Initio) and once-monthly subcutaneously injected Perserin® (RBP-7000); (ii) the treatment of acutely exacerbated schizophrenia with lumateperone, a novel antipsychotic modulating dopamine, serotonin and, via D1 agonism, glutamatergic transmission50 that is currently being evaluated by the FDA for approval for acutely exacerbated schizophrenia, and (iii) the combination of samidorphan plus olanzapine in one pill for the reduction of body weight gain with ALKS3831 at 3 and 6 months,123,125,126 while maintaining olanzapine’s efficacy.124,127,128

Injections in the initial phases of LAI treatment,100,111,114 leading to FDA approval of Aripiprazole Lauroxil NanoCrystal® Dispersion (ALNCD; Aristada Initio) and once-monthly subcutaneously injected Perserin® (RBP-7000); (ii) the treatment of acutely exacerbated schizophrenia with lumateperone, a novel antipsychotic modulating dopamine, serotonin and, via D1 agonism, glutamatergic transmission50 that is currently being evaluated by the FDA for approval for acutely exacerbated schizophrenia, and (iii) the combination of samidorphan plus olanzapine in one pill for the reduction of body weight gain with ALKS3831 at 3 and 6 months,123,125,126 while maintaining olanzapine’s efficacy.124,127,128
Acknowledgements

We thank Jonathan M. Meyer, MD, clinical professor in the Department of Psychiatry at the University of California, San Diego School of Medicine in La Jolla, CA, for sharing a presentation given at NEI congress 2018 that contained some of the reviewed material.

Funding

No funding declared.

Disclosure

Ms. Krogmann, Peters, von Hardenberg, Dr. Bödeker, and Mr. Nöhles have nothing to disclose.

Dr. Correll has been a consultant and/or advisor to or has received honoraria from: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Boehringer-Ingelheim, Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a shareholder of LB Pharma.

REFERENCES:

1. Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Prim. 2015; 1: 15069. doi: 10.1038/nrdp.2015.69
2. DiBonaventura M, Gabriel S, Duplay L, et al. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012; 12(1): 20. doi: 10.1186/1471-244X-12-20
3. National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. NICE Guidelines. https://www.nice.org.uk/guidance/cg178. Accessed June 27, 2019.
4. Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci. 2010; 12(3): 345-357.
5. Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017; 174(10): 927-942. doi: 10.1176/appi.ajp.2017.16121358
6. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet Lond Engl. 2012; 379(9831): 2063-2071. doi: 10.1016/S0140-6736(12)62039-6
7. Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013; 18(1): 53–66. doi: 10.1038/mp.2011.143
8. Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018; 17(2): 149-160. doi: 10.1002/wps.20516
9. Kishimoto T, Hagi K, Nitta M, et al. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019; 18(2): 208-224.
10. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenic efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007; 68(2): e04. doi: 10.4088/JCP.02077-o4
11. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2224-2260. doi: 10.1016/S0140-6736(12)61766-8
12. Murray CJL, Vos T, Lopez A., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet Lond Engl. 2012; 380(9859): 2197-2233. doi: 10.1016/S0140-6736(12)61689-4
13. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet Lond Engl. 2012; 380(9859): 2163-2196. doi: 10.1016/S0140-6736(12)61729-2
14. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet Lond Engl. 2012; 380(9859): 2129-2143. doi: 10.1016/S0140-6736(12)61680-8
15. Correll CU. The prevalence of negative symptoms in schizophrenia and their impact on patient functioning and course of illness. J Clin Psychiatry. 2013; 74(2): e04.
16. Insel TR. Rethinking schizophrenia. Nature. 2010; 468(7321): 187-193. doi: 10.1038/nature09552
17. McGorry PD, Yung AR, Bechdolf A, et al. Back to the future: predicting and reshaping the course of psychotic disorder. Arch Gen Psychiatry. 2008; 65(1): 25-27. doi: 10.1001/archgenpsychiatry.2007.9
18. Mosolov SN, Pota pow AV, Ushakov UV. Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population. Ann Gen Psychiatry. 2012; 11: 1. doi: 10.1186/1744-859X-11-1
19. Millan MJ, Fone K, Steckler T, et al. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014; 24(5): 645-692. doi: 10.1016/j.euroneuro.2014.03.008
20. Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014; 19(Suppl 1): 38-52; quiz 35-37. doi: 10.1017/CN S Spectr.2014.3
21. Correll CU, Rubio JM, Incedo-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017; 74(7): 675-684. doi: 10.1001/jamapsychiatry.2017.0624
22. Solmi M, Murre A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017; 13: 757-777. doi: 10.2147/TCRM.S117321
23. Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015; 14(2): 119-136. doi: 10.1002/wps.20204
24. Carbon M, Kane JM, Leucht S, et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. *World Psychiatry*. 2018; 17(3): 330-340. doi: 10.1002/wps.20579

25. Carbon M, Heish C-H, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. *J Clin Psychiatry*. 2017; 78(3): e264-e278. doi: 10.4088/JCP.16i10832

26. Vancampfort D, Firth J, Correll CU, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. *World Psychiatry*. 2019; 18(1): 53-66. doi: 10.1002/wps.20614

27. Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. *World Psychiatry*. 2017; 16(2): 163-180. doi: 10.1002/wps.20420

28. Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. *World Psychiatry*. 2016; 15(2): 166-174. doi: 10.1002/wps.20309

29. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. *World Psychiatry*. 2015; 14(3): 339-347. doi: 10.1002/wps.20252

30. Nielsen J, Correll CU, Manu P, et al. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? *J Clin Psychiatry*. 2013; 74(6): 603-613; quiz 613. doi: 10.4088/JCP.12r08064

31. Siskind D, Siskind V, Kiseley S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. *Can J Psychiatry Rev Can Psychiatr*. 2017; 62(11): 772-777. doi: 10.1177/07067437177181167

32. Howes OD, McCatchreon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. *Am J Psychiatry*. 2017; 174(3): 216-229. doi: 10.1176/appi.ajp.2016.16050503

33. Yang AC, Tsai SJ. New targets for schizophrenia treatment beyond the dopamine hypothesis. *Int J Mol Sci*. 2017; 18(8): 1689. doi: 10.3390/ijms18081689

34. Garay RP, Citrome L, Samalin L, et al. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. *Expert Opin Pharmacother*. 2016; 17(7): 921-936. doi: 10.1517/14656566.2016.1149164

35. Köster L-S, Carbon M, Correll CU. Emerging drugs for schizophrenia: an update. *Expert Opin Emerg Drugs*. 2014; 19(4): 511-531. doi: 10.1517/14726214.2014.958148

36. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. *World Psychiatry*. 2013; 12(3): 216-226. doi: 10.1002/wps.20060

37. Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. *Schizophr Bull*. 2018; 44(3): 603-619. doi: 10.1093/schbul/sbx090

38. Misawa F, Kishimoto T, Hagi K, et al Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. *Schizophr Res*. 2016; 176(2-3): 220-230. doi: 10.1016/j.schres.2016.07.018

39. Hashb JM, Kishimoto T, Correll CU, et al. Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. *Curr Opin Psychiatry*. 2015; 28(3): 216-221. doi: 10.1097/YCO.0000000000001160

40. Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. *J Clin Psychiatry*. 2013; 74(10): 957-965. doi: 10.1097/JCP.0b013e318284a440

41. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. *J Clin Epidemiol*. 2013; 66(Suppl 8): S37-S41. doi: 10.1016/j.jclinepi.2013.01.012

42. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. *Schizophr Bull*. 2014; 40(1): 192-213. doi: 10.1093/schbul/sbu150

43. Ibrah Bih C, Chen T, Nunn AW, et al. Molecular targets of cannabidiol in neurological disorders. *Neurother J Am Soc Exp Neurother*. 2015; 12(4): 699-730. doi: 10.1038/s41331-015-0377-3

44. White CM. A review of human studies assessing Cannabidiol’s (CBD) therapeutic actions and potential. *J Clin Pharmacol*. 2019; 59: 923-934. doi: 10.1002/jcph.1387

45. Leweke FM, Mueller JK, Lange B, et al. Role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention. *CNS Drugs*. 2018; 32(7): 605-619. doi: 10.1007/s40263-018-0539-z

46. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. *Am J Psychiatry*. 2018; 175(3): 225-231. doi: 10.1176/appi.ajp.2017.17030325

47. Sokoloff P, Le Foil B. The dopamine D3 receptor, a quarter century later. *Eur J Neurosci*. 2017; 45(1): 2-19. doi: 10.1111/ejn.13390

48. Bitter I, Lieberman JA, Gaudoux F, et al. Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. *Neuropsychopharmacology*. 2019. doi: 10.1038/s41386-019-0355-2

49. Davis RE, Correll CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. *Expert Rev Neurother*. 2016; 16(6): 601-614. doi: 10.1080/14737575.2016.1174577

50. Vanover KE, Dimitrienko A, Glass SJ, et al. Lumateperone (ITI-007) for the treatment of schizophrenia: overview of placebo-controlled clinical trials and an open-label safety switching study. *APA Conf Poster Present P5-178, San Francisco, USA, 2018."

51. Snyder CL, Vanover KE, Zhu H, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. *Psychopharmacology (Berl)*. 2015; 232(3): 605-621. doi: 10.1007/s00213-014-3704-1

52. Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. *Biol Psychiatry*. 2016; 79(12): 952-961. doi: 10.1016/j.biopsych.2015.08.026

53. Vanover KE, O’Gorman C, Glass SJ, et al. Favorable clinical safety profile for lumateperone (ITI-007) switching from standard-of-care antipsychotic therapy in patients with schizophrenia. *ACNP Conf 2017 Poster Present T189, California, USA, 2018.

54. Vanover KE, Correll CU, Weingart M, et al. Long-term safety for lumateperone (ITI-007) in the treatment of schizophrenia. *ACNP Conf 2018 Poster Present T184, Hollywood, USA."
98. Alkermes, Inc., Data on file. Clinical Study Report ALK9072-B102.

95. Lane H-Y, Lin C-H, Green MF, et al. Correlation CU, Citrome L, Haddad PM, et al. Moschetti V, Desch M, Goetz S, et al. Effect of Lu AF35700 in Patients with Treatment-Resistant Schizophrenia: a randomized, double-blind, placebo-controlled trial. *Eur Arch Psychiatry Clin Neurosci*. 2017; 267(5): 367-377. doi: 10.1007/s00406-013-0399-y

96. Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia - Full Text View, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT002832037. Accessed April 1, 2019.

85. This Study Tests Whether BI 425809 Together with Brain Training Using a Computer Improves Mental Functioning in Patients with Schizophrenia - Full Text View, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03859973. Accessed April 1, 2019.

88. Boggs DL, Surti T, Gupta A, et al. The effects of cannabinoid (CBD) on cognition and symptoms in outpatients with chronic schizophrenia: A randomized placebo controlled trial. *Psychopharmacology (Berl)*. 2018; 235(1): 1923-1932. doi: 10.1007/s00213-018-4855-9

89. Effect of Lu AF35700 in Patients with Treatment-Resistant Schizophrenia - Full Text View, ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02717195. Accessed March 28, 2019.

90. Efficacy of Lu AF35700 in Patients with Early-in-Disease or Late-in-Disease Treatment-Resistant Schizophrenia - Full Text View, ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03230864. Accessed March 28, 2019.

92. Efficacy and Safety of Adjunctive Paliperidone for the Treatment of Schizophrenia (ENHANCE-1) - Full Text View, ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02970292. Accessed March 28, 2019.

93. ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Paliperidone as Adjunctive Treatment for Patients with Schizophrenia, Nasdaq.com. https://investor.acadia.com/news-releases/news-release-details/acadia-updates-clinical-phase-iii-study-lu-af35700-treatment. Accessed March 11, 2019.

94. Lin C-H, Chin C-H, Chang Y-C, et al. Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. *Biol Psychiatry*. 2018; 84(6): 422-432. doi: 10.1016/j.biopsych.2017.12.006

95. Lane H-Y, Lin C-H, Green MF, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. *JAMA Psychiatry*. 2013; 70(12): 1267-1273. doi: 10.1001/jama.psychiatry.2013.2159

96. Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. *J Clin Psychiatry*. 2016; 77(Suppl 3): 1-24. doi: 10.4088/JCP.15m0321

97. Alkermes, FDA Approves ARISTADA INITIOM for the Initiation of ARISTADA® for Schizophrenia. Press Release, July 2018. http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2356744.

98. Alkermes, Inc., Data on file. Clinical Study Report ALK9072-B102. Walth MA. 2017.

99. Hard ML, Wehr Y, Sadler BM, et al. Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil. *Eur J Drug Metab Pharmacokinet*. 2018; 43(2): 239-249. doi: 10.1007/s13318-017-0440-z

100. Wolling D, Hard ML, Wehr A, et al. Aripiprazole lauroxil nanocrystal dispersion: a potential 1-day initiation regimen for long-acting aripiprazole lauroxil. *Present Anna Meet Am Psychiat Assoc*. 2018.

101. Mathews M, Gopal S, Nuamah I, et al. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. *Neuropsychiatr Dis Treat*. 2019; 15: 1365-1379. doi: 10.2147/NDT.S197225

102. Indivior. PERSERIS (riperpazine) for extended-release injectable suspension, for subcutaneous use. Prescr Inf. July 2018. http://www.indivior.com/wp-content/uploads/2018/07/FDA-Label-revised.pdf.

103. Indivior. FDA approves PERSERIS (riperpazine) for extended-release injectable suspension for the treatment of schizophrenia in adults. Press Release. July 2018. http://indivior.com/wp-content/uploads/2018/07/PERSERIS-Press-Release-FINAL.pdf.

104. Citrome L. Sustained-release risperidone via subcutaneous injection: a systematic review of RBP-7000 (PERSERISM) for the treatment of schizophrenia. *Clin Schizophr Relat Psychoses*. 2018; 12(3): 130-141. doi: 10.3371/csrp.C1.101118

105. Patel DB. A review on atigrel drug delivery system. *J Global Pharma Technol*. 2010; 2:85-90.

106. Gomeni R, Heidbreder C, Fudala PJ, et al. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone. *J Clin Pharmacol*. 2013; 53(10): 1010-1019. doi: 10.1002/jcph.141

107. Lafront CM, Gomeni R, Zheng B, et al. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. *Clin Pharmacokinet*. 2014; 53(6): 533-543. doi: 10.1007/s00262-014-0132-7

108. Iszt JJ, Nadipelli VR, Kouassi A, et al. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. *Schizophr Res*. 2016; 174(3–4): 126-131. doi: 10.1016/j.schres.2016.03.020

109. Nasser AF, Henderson DC, Fava M, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. *J Clin Psychopharmacol*. 2016; 36(2): 130-140. doi: 10.1097/JCP.0000000000000479

110. Ivatiri V, Copalakrishnan M, Gobburu JVS, et al. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting atigrel formulation of risperidone: E-R analysis of RBP-7000, a long acting risperidone formulation. *Br J Clin Pharmacol*. 2017; 83(7): 1476-1496. doi: 10.1111/bcp.13246

111. Graham J, Fava M, Newcomer J, et al. Monthly extended-release risperidone injections (RBP-7000) in the treatment of schizophrenia: results from two phase III trials. *Present Anna Meet Am Psychiat Assoc*. 2018.

112. Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Patients with Schizophrenia - Full Text View, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03503318. Accessed June 11, 2019.
113. A Study to Test if TV-46000 Is Safe for Maintenance Treatment of Schizophrenia - Full Text View. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03160521. Accessed April 2, 2019.

114. Laboratoryos Farmacéuticos ROVI – DORIA Phase III trial hits primary endpoint. *Edison*. https://www.edisongroup.com/publication/doria-phase-iii-trial-hits-primary-endpoint/23705. Accessed March 28, 2019.

115. Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients with Acute Schizophrenia - No Study Results Posted. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/results/NCT03160521. Accessed April 2, 2019.

116. Solmi M, Pigato G, Kane JM, *et al.*. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. *Drug Des Devel Ther*. 2018;12:1215-1238. doi: 10.2147/DDDT.S133205

117. Correll CU, Manu P, Olshanskiy V, *et al.*. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. *JAMA* *J Am Med Assoc*. 2009;302(16):1765–1773. doi: 10.1001/jama.2009.1549

118. De Hert M, Detraux J, van Winkel R, *et al.*. Antipsychotic drugs and obesity. *Nat Rev Endocrinol*. 2010;6:177–188. doi: 10.1038/nrendo.2011.156

119. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. *Trends Mol Med*. 2011;17(2):97-107. doi: 10.1016/j.molmed.2010.06.010

120. Leucht S, Cipriani A, Spineli L, *et al.*. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet Lond Engl*. 2013;382(9896):951-962. doi: 10.1016/S0140-6736(13)60733-3

121. Lieberman JA, Stroup TS, McEvoy JP, *et al.*. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med*. 2005;353(12):1209-1223. doi: 10.1056/NEJMoa051688

122. Wentland MP, Lou R, Lu Q, *et al.*. Syntheses of novel high affinity ligands for opioid receptors. *Bioorg Med Chem Lett*. 2009;19(8):2289-2294. doi: 10.1016/j.bmcl.2009.02.078

123. Silverman BL, Martin W, Memisoglu A, *et al.*. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. *Schizophr Res*. 2018;195:245-251. doi: 10.1016/j.schres.2017.10.014

124. Sun L, McDonnell D, von Molke L. Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanzapine and samidorphan, in adult subjects with schizophrenia. *Clin Ther*. 2018;40(11):1845-1854.e2. doi: 10.1016/j.clinthera.2018.09.002

125. Martin WF, Correll CU, Weiden PJ, *et al.*. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. *Am J Psychiatry*. 2019;176:457-467. doi: 10.1176/appi.ajp.2018.18030280

126. Correll C, Kahn R, Silverman B, *et al.*. Combination of olanzapine and samidorphan limits the weight gain observed with olanzapine alone: results from the phase 3 ENLIGHTEN-2 schizophrenia study. Presented at the Schizophrenia International Research Society (SIRS) meeting; April 10, 2019; Orlando, Florida, USA.

127. Alkermes Announces Positive Topline Results from ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients with Schizophrenia. https://www.prnewswire.com/news-releases/alkermes-announces-positive-topline-results-from-enlighten-2-phase-3-study-of-alks-3831-in-patients-with-schizophrenia-300757319.html. Accessed March 28, 2019.

128. Potkin SG, Kanovic J, Silverman BL, *et al.*. A phase 3 study to determine the antipsychotic efficacy and safety of ALKS 3831 in adult patients with acute exacerbation of schizophrenia. *CNS Spectr*. 2019;24(1):187-188. doi: 10.1017/S1092852919000208

129. Alkermes Announces Positive Topline Results from ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients with Schizophrenia. https://finance.yahoo.com/news/alkermes-announces-positive-topline-results-120800021.html. Accessed March 28, 2019.

130. Correll CU, What are we looking for in new antipsychotics? *J Clin Psychiatry*. 2011;72(Suppl 1):9-13. doi: 10.4088/JCP.1007s1.02

131. Correll CU, Vanover KE, Glass SJ, *et al.*. Favorable clinical safety profile for lumateperone 8ITI-007 - switching from standard-of-care (SOC) antipsychotic therapy in patients with schizophrenia. CINP Conf 2018 Poster Present PM161, Vienna Austria.
Optional Posttest and CME Certificate

CME Credit Expires: May 15, 2022

Posttest Study Guide

The posttest can only be submitted online. The below posttest questions have been provided solely as a study tool to prepare for your online submission. Fax/mailed copies of the posttest cannot be processed and will be returned to the sender. If you do not have access to a computer, contact NEI customer service at 888-535-5600.

1. Phosphodiesterase 10A (PDE10) inhibitors currently being investigated, such as TAK-063 and MK-8189, are expected to target both ___________ and ___________ dysfunction in schizophrenia.
   A. Cholinergic, serotonergic
   B. Dopaminergic, glutamatergic
   C. Dopaminergic, serotonergic
   D. Histaminergic, glutamatergic

2. Which of the following investigational agent being tested as a monotherapy does not have a non-dopaminergic mechanism
   A. ALKS3831
   B. LuAF-11167
   C. MIN-1010

3. Lumateperone (ITI-007), an investigational agent for the treatment of schizophrenia, simultaneously modulates which of the following:
   A. Dopamine
   B. Glutamate
   C. Serotonin
   D. A and C
   E. B and C
   F. A, B, and C

4. RBP-7000 (Perseris), a recently FDA-approved long-acting injectable (LAI) formulation of risperidone, requires an oral risperidone supplementation after the first subcutaneous injection.
   A. True
   B. False

5. The investigational agent sodium benzoate is a . . . .
   A. d-amino acid oxidase (DAAO) inhibitor
   B. glycine transporter-1 (GlyT-1) inhibitor
   C. phosphodiesterase 10A (PDE10) inhibitor

Optional Online Posttest and CME Certificate Instructions

1. Read the article
2. Complete the posttest, available only online at www.neiglobal.com/CME (under “CNS Spectrums”)
3. Print your certificate (passing score = 70% or higher)

Questions? call 888-535-5600, or email CustomerService@neiglobal.com